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Background: Polypharmacy and potentialy inappropriate medication (PIM) use are common and 
associated  with considerable  morbidity,  yet they are often modifiable risk factors. However, 
some  PIM  use is a result  of limited information  on medication safety across patient kidney 
function. One such  medication, spironolactone, an aldosterone antagonist indicated for  heart 
failure, has  been  demonstrated in clinical trials to reduce morbidity and  mortality among 
individuals with normal renal function, but its safety in those with chronic kidney disease (CKD) 
is unclear. 
 
Methods: We  used longitudinal  data from the Atherosclerosis  Risk in  Communities (ARIC) 
study to  quantify  PIM  use  by estimated  glomerular filtration rate (eGFR), and to assess the 
relationship between polypharmacy, PIM use, and subsequent hospitalization and death in older 
adults. We used commercial claims data from MarketScan and electronic health record data from 
the Geisinger  Health  System to identify predictors of spironolactone initiation among  patients 
with  heart failure, and used target trial emulation to characterize the risk  of  hyperkalemia and 
acute kidney injury (AKI) with spironolactone use among patients using loop diuretics. 
 
Results:  Participants in  ARIC (N=6,392) with  CKD reported  more  medications than those 
without  CKD (p<0.001), and PIM use based  on  kidney function was  prevalent (36%) among 
those with eGFR <30 ml/min/1.73m2. More concurent medications were associated with higher 
risks of  hospitalization and  death,  but  PIM  use  was  not, and there were no  diferences in the 
relative risks associated  with  greater  numbers  of  medications  by  CKD status. Among  patients 
with incident heart failure in MarketScan (N=22,956) and Geisinger (N=16,547), 7.0% and 9.9% 
initiated spironolactone within two years, respectively. Patients with eGFR <30 were least likely 
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to initiate spironolactone compared to patients  with eGFR  60-89 (meta-analyzed  hazard ratio 
[HR]:  0.61,  95% confidence interval [CI]:  0.44-0.83). In  Geisinger patients  with  heart failure 
using loop diuretics (N=17,110), spironolactone initiation  was associated  with increases in 
hyperkalemia and  AKI risk compared to use  of loop  diuretics alone (HR  1.69 [CI:  1.35-2.10], 
and HR 1.12 [CI: 1.00-1.26], respectively), with no observed diferences in the relative risk of 
either outcome associated with spironolactone by eGFR. 
 
Conclusions:  Polypharmacy and PIM use were common, with greater numbers of medications 
associated with greater risk of hospitalization or death. Spironolactone initiation was uncommon 
within two  years of  heart failure diagnosis, and least likely among patients  with lower kidney 
function. The addition of spironolactone to loop diuretics increased the risk of hyperkalemia, and 
more modestly, AKI. Improved data on medication safety in patients with CKD are needed. 
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1.1.1 Potentialy inappropriate medication (PIM) use and polypharmacy 
 
Potentialy inappropriate medication (PIM) use as a consequence of unnecessary polypharmacy 
or using medications that are contraindicated based on kidney function is common, costly, and 
the cause of substantial morbidity.(1) The impact of PIMs is especialy great among patients at 
an increased risk of adverse drug efects, and those with high medication burdens. For example, 
vulnerable patients like older adults or those with chronic kidney disease (CKD) are prescribed 
many medications concurently including those with safety profiles that become complicated by 
age-related metabolic factors and renal physiology.(2) In patients with heart failure, where both 
polypharmacy(3) and  CKD1(4) are prevalent, the adverse efects associated  with PIM  use can 
range from  minor to severe, but it is often associated  with worse patient  outcomes.  In the 
context of CKD, this can be further exacerbated by medications that are primarily eliminated by 
the kidneys, or inherently nephrotoxic, as these patients may not be able to adequately clear the 
drug or its active and/or toxic metabolites, resulting in exaggerated pharmacologic efects or life-
threatening conditions like  hyperkalemia.(5)  To  prevent this, some  drugs require a  dose 
adjustment in  CKD to accommodate their pharmacokinetics (PK), and other  drugs are 
contraindicated at specific estimated glomerular filtration rate (eGFR) thresholds to mitigate any 
potential risks. While unnecessary polypharmacy may be preventable with beter coordination of 
care  between  providers, mitigating the risk for redundant  medications,  drug-drug interactions, 
and inappropriate dosing,(6-8) the risks associated with PIM use based on kidney function are 
not always  modifiable.  Because  of limited therapeutic  options for  patients with  CKD, 
                            
1 Roughly 12-74% of patients with heart failure have CKD; prevalence estimates are highly dependent on study 
population, heart failure severity, and definition of CKD. 
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medications are sometimes prescribed in  patients  where their use  may  not  be necessarily 
recommended but where any benefits are presumed to outweigh their known risks. Separately, 
data  on the safety and eficacy of certain  medications for  use in those  with reduced  kidney 
function are chalenged by insuficient pre-market study and regulatory frameworks.(9-11)  
 
1.1.2 Guidelines for medication use in patients with reduced kidney function 
 
Many approved medications  do  not  have adequate information  on appropriate  use in  patients 
with  CKD.(9,  12-14)  The  U.S.  Food and  Drug  Administration (FDA) issued an  updated 
“Guidance for Industry” in  2010 recommending sponsors conduct PK studies in  patients  with 
CKD for  new  drug applications (NDA), specificaly  when the  drug is expected to  be  used in 
patients with CKD, and when reduced renal function may inhibit adequate clearance of the drug 
or its metabolites.(15) Although this guidance focuses on drugs that are mainly renaly-cleared,2 
FDA does recommend renal studies for drugs that are cleared by non-renal routes, such as those 
secreted in bile.(15) While the impact of the FDA “Guidance” has been positive in that a greater 
proportion of NDAs contain renal PK data, there are stil many drugs where these studies have 
not  been conducted. In an internal  FDA survey, after the first “Guidance” in  1998,  61%  of 
submited  NDAs  between  2003 and  2007 for  new  molecular entities  had renal PK studies, as 
opposed to  44%  prior to the  guidance.(16)  Despite ostensible improvements in colecting 
pharmacologic data  on those  with  CKD, the safety and eficacy  of  many  medications in this 
population of patients with multifaceted and evolving medical needs are stil relatively unknown, 
as those with reduced renal function are systematicaly excluded from clinical trials;(10, 11, 17) 
this particularly afects legacy medications approved many years ago. Drug manufacturers justify 
excluding adults  with reduced renal function from  pre-market testing  because  of their  higher 
                            
2 Those meeting an Agency standard of greater than 30% of the dose excreted unchanged in the urine. 
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propensity for adverse drug efects compared to adults with preserved kidney function, and the 
altered  PK  of a  drug  when  used in these  patients;(10,  11,  16,  18)  curently,  no regulation 
mandates their inclusion in clinical studies  during  drug  development. Al  of this creates 
uncertainly in the clinical application  of some  medications for  use in patients  with CKD, and 
although  published  guidelines and  other resources  do exist, conflicting information is  often 
provided on when and how to use certain medications based on kidney function.(9)  There are 
deleterious consequences to this  uncertainty in that  potentialy  useful  medications  may  be 
withheld unnecessarily from  CKD  patients, and conversely,  when some  medications are 
prescribed, it may  be in the context  of an  uncertain risk  profile across the spectrum  of  kidney 
function. 
 
1.1.3 Spironolactone as a case study for unclear utilization and safety in CKD 
1.1.3.1 Spironolactone’s indication and pharmacologic properties 
Spironolactone (Aldactone®), a potent mineralocorticoid receptor antagonist  medication 
approved in  1960, exemplifies the  uncertainty that arises from limited safety  data  on a 
medication with known efectiveness. Spironolactone is an aldosterone antagonist indicated for 
the treatment of heart failure, primarily those with New York Heart Association class II or IV 
heart failure  with severe left  ventricular systolic  dysfunction, and  other conditions including 
hyperaldosteronism and hypertension.(19) Spironolactone antagonizes aldosterone via 
competitive binding of receptors in the late distal convoluted tubule responsible for aldosterone-
dependent sodium-potassium (Na+/K+) exchange, rendering the receptor complex inactive and 
preventing its translocation into the  nucleus  of target cels; this inhibits the  production  of 
mediator proteins responsible for stimulating Na+/K+ exchange.(20-22)  By inhibiting Na+/K+ 
exchange, spironolactone acts as a potassium-sparing diuretic alowing more sodium to pass into 
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the renal colecting  duct, and thus  promoting diuresis. Spironolactone  has ~65%  oral 
bioavailability and a relatively slow onset of action. It is rapidly metabolized by the liver (~1.6 
hour  half-life) into several active  metabolites (primarily sulfur-containing  molecules)  with 
relatively long half-lives (13.8 to 16.5 hours), and is mostly excreted in the urine.(19, 23)  
 
1.1.3.2 Spironolactone’s cardioprotective and renoprotective efects 
Clinical trial data suggest that the addition of spironolactone to standard medication regimens in 
heart failure, including angiotensin-converting-enzyme inhibitors (ACEi), angiotensin I receptor 
blockers (ARBs), and β-blockers, is an efective treatment strategy in mitigating morbidity and 
mortality associated  with  heart failure. In  1999, the Randomized  Aldactone  Evaluation  Study 
(RALES) established spironolactone’s efectiveness in reducing  heart failure re-hospitalization 
and  death in  patients  with  heart failure  with reduced ejection fraction (HFrEF) also on loop 
diuretics. More than a decade later, the Treatment of Preserved Cardiac Function Heart Failure 
with an Aldosterone Antagonist (TOPCAT) trial assessed spironolactone’s utility in heart failure 
with  preserved ejection fraction (HFpEF) and found similar reductions  with respect to  heart 
failure re-hospitalization,  but  not  mortality. Other randomized studies (24,  25)  have 
coroborated the  beneficial efects  of spironolactone treatment in various heart failure 
populations, hypothesizing its  pharmacologic efects as an aldosterone antagonist are 
multifaceted and may benefit patients in various ways, including preserving kidney function. 
 
Aldosterone is critical in heart failure and CKD pathophysiology.  In heart failure, aldosterone 
antagonists can  prevent cardiovascular remodeling as a result  of  heart failure  progression, and 
manage edematous states.(19, 21) Because spironolactone is a pleiotropic hormone, it can bind 
to  mineralocorticoid receptors in  various types  of tissues including  myocardium, endothelium, 
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and vascular smooth muscles, promoting cardioprotective efects.(20, 26) Edwards et al. found 
that spironolactone use was associated with reduced left ventricular mass and arterial stifness in 
patients with early stage CKD.(27) Studies have also shown that inhibiting the renin-angiotensin-
aldosterone system (RAAS) can slow the progression of CKD by reducing systemic arterial and 
intraglomerular  pressure, and  by  blocking the efects  of angiotensin I  on the  production  of 
mesangial cels, and initiating fibrosis.(28-32) Although ACEi and ARBs act on this system with 
renoprotective efects, they  do  not  meaningfuly suppress aldosterone leading to “aldosterone 
escape.”(29, 31, 33, 34) Evidence suggests that aldosterone contributes to nephropathy,(32, 35) 
and it is hypothesized that spironolactone’s further blockade of the RAAS may be beneficial in 
mitigating  decline in renal function.(30,  31,  33)  Prolonged  RAAS activation also  has adverse 
cardiovascular efects including increases in  myocardial extracelular  matrix fibrilar colagen, 
left ventricular hypertrophy, and myocardial stifness, and can lead to heart failure.(34) 
 
Since 2000, dozens of clinical trials funded by government and industry sponsors investigating 
spironolactone’s eficacy in treating  various cardiomyopathies, liver  diseases, and  kidney 
diseases have been completed or are ongoing. The clinical trials in patients with kidney disease 
have investigated its eficacy among those  with  varying  degrees  of  kidney  dysfunction, from 
mild  or  moderate  CKD, looking at cardiovascular endpoints like  blood  pressure and 
cardiovascular-related  mortality,  but also renal endpoints like changes in  proteinuria and 
mitigating further decline in kidney function. 
 
1.1.3.3 Spironolactone’s safety in reduced kidney function 
The single ingredient formulation is not recommended for those with significant impairment of 
renal function due to their increased risk for  primarily  hyperkalemia and acute  kidney injury 
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(AKI);(19-21) however, published guidelines have been somewhat inconsistent with respect to 
what level  of  kidney function  use is contraindicated.(36,  37) Spironolactone  was approved 
without renal safety studies  which  makes it  dificult to adequately establish a risk  profile for 
hyperkalemia and  AKI across the spectrum  of  kidney function.   Even in the  RALES and 
TOPCAT clinical trials, patients with reduced renal function were not included because of their 
increased risk for hyperkalemia and AKI, and therefore, despite a long-marketing history there is 
a  paucity of published  data  on its  potentialy  variable risks in this group. In several smal 
randomized controled trials (26, 38-40) looking at the efect of the mineralocorticoid receptor 
antagonists (including spironolactone) on  various cardiovascular endpoints in  patients  with 
advanced  CKD and those  on  dialysis,  hyperkalemia  was infrequent,  with similar rates to the 
placebo groups; however, these studies were conducted in highly-controled clinical setings, and 
include  patients  on eplerenone  which is less  potent than spironolactone.  The spironolactone 
label does  give general recommendations  on  dosing within ranges of eGFR,  but it  does  not 
utilize a specific contraindicated eGFR threshold. The label also recommends spironolactone not 
be  used  with  other  potassium-sparing  diuretics,  or  during  potassium supplementation, and 
cautions against use with ACEi, ARBs, and nonsteroidal anti-inflammatory drugs (NSAID), as 
these may also increase the risk of hyperkalemia and AKI.(19) 
 
While the potential for spironolactone-induced hyperkalemia and AKI is wel understood based 
on the drug’s mechanism of action, it is not wel quantified, and the specific impact of patient 
kidney function  on these risks remains  uncertain. In the landmark RALES trial, not  only  were 
patients with eGFR less than 30 ml/min/1.73m2 excluded, enroled patients were dose-adjusted 
or discontinued based on changes in their serum creatinine or potassium.(41) Hyperkalemia and 
AKI were very rare in RALES, and other studies using similar exclusion criteria and monitoring. 
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(42,  43)  Several clinical trials are curently  ongoing and  may lead to expanded  use in  heart 
failure and  non-heart failure  populations, including those  with advanced  CKD;  presumably 
safety  data  wil emerge from these studies. Nevertheless, given its rather convincing 
cardioprotective efects, and potential utility in mitigating CKD progression, in clinical practice 
today, patients use spironolactone at  various levels  of kidney function (44) with comorbidities 
and concomitantly with medications that put them at risk of hyperkalemia and AKI independent 
of their kidney function or spironolactone  use. For that reason, isolating the direct efects  of 
spironolactone on the subsequent development of hyperkalemia and AKI in the context of real-
world use is needed to beter inform curent clinical practice and labeling. 
 
1.2 Objectives 
1) a) To characterize medication use across kidney function in older adults, with a focus on 
polypharmacy and medications  deemed “potentialy inappropriate”  based  on  kidney 
function, or age, using data from the Atherosclerosis Risk in Communities (ARIC) study 
b) To quantify the risk of hospitalization and death among those with polypharmacy and 
PIM use, looking for diferences by CKD status 
2) To assess the corelates and likelihood  of spironolactone initiation, and  discontinuation 
among initiators, in patients  with incident  heart failure across the spectrum  of kidney 
function,  using  data from  Truven  MarketScan  Commercial  Claims and  Encounters 
database, and electronic health record (EHR) data from the Geisinger Health System 
3) To quantify the risks of hyperkalemia and AKI associated with spironolactone use among 
patients with heart failure on loop diuretics, and to assess for diferential risk by kidney 
function, using EHR data from the Geisinger Health System 
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2 Kidney function,  polypharmacy, and  potentialy inappropriate 
medication use in a community-based cohort of older adults3 
 
2.1 Abstract 
Background: Chronic  kidney  disease (CKD) aflicts  many  older adults, and increases the risk 
for medication-related adverse events. 
Objective: To assess the  prevalence and associated  morbidity and  mortality  of  polypharmacy 
(use of several medications concurently), and potentialy inappropriate medication (PIM) use in 
older adults, looking for diferences by CKD status. 
Methods:  We  quantified  medication and  PIM  use (from  Beers criteria, the  Screening  Tool  of 
Older People’s Prescriptions, and Micromedex®) by level of estimated glomerular filtration rate 
(eGFR) for participants 65 years or older atending a baseline study visit in the Atherosclerosis 
Risk in  Communities study (N=6,392).  We  used zero-inflated  negative  binomial and  Cox 
proportional hazards regressions to assess the relationship between baseline polypharmacy, PIM 
use, and subsequent hospitalization and death.  
Results: Mean age at baseline was 76 (+5) years, 59% were female, and 29% had CKD (eGFR 
<60  ml/min/1.73m2).  Overal,  participants reported  6.1 (+3.5)  medications and  2.3 (+2.2) 
vitamins/supplements; 16% reported >10 medications; 31% reported a PIM based on their age. 
On average, participants with CKD reported more medications. A PIM based on kidney function 
was  used  by  36%  of those  with eGFR  <30  ml/min/1.73m2.  Over a  median  of  2.6  years,  more 
concurent  medications  were associated  with  higher risk  of  hospitalization and  death,  but  PIM 
                            
3 Secora A, Alexander GC, Balew SH, Coresh J, Grams ME. Kidney Function, Polypharmacy, and Potentialy 
Inappropriate Medication Use in a Community‑Based Cohort of Older Adults. Drugs & Aging. 2018;35:735-750. 
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use  was  not.  While those  with  CKD  had  higher absolute risks, there  was  no  diference in the 
relative risks associated with greater numbers of medications by CKD status. 
Conclusion: Polypharmacy and  PIM  use  were common,  with  greater  numbers  of  medications 
associated with higher risk of hospitalization and death; relative risks were similar for those with 
and without CKD. 
 
2.2 Introduction 
Older adults constitute a vulnerable and growing segment of the population with a particularly 
high burden of comorbid conditions like chronic kidney disease (CKD), which afects up to 40% 
of  older adults in the  United  States.(45,  46)  As a consequence  of  more comorbidities, 
medication use in older adults is high, yet drug metabolism and clearance may change with age, 
especialy in the seting of CKD.(2) Common in older adults,(6, 47-52) polypharmacy has been 
linked to  higher risk of adverse  drug-drug interactions, (6-8,  47,  48,  50,  51,  53,  54)  and 
morbidity and mortality. (53, 55-63) 
 
Another  medication-related risk factor that  may  be associated  with  morbidity and  mortality in 
older adults, particularly those with CKD, is potentialy inappropriate medication (PIM) use. (53, 
62,  64)  Pharmacy and  published  medication references suggest that  PIMs  be avoided  or 
carefuly monitored in the seting of older age or CKD to mitigate preventable adverse efects. 
Certain drugs and drug metabolites are excreted by the kidney, necessitating dose adjustment or 
drug avoidance in those  with reduced  kidney function to  prevent  potentialy toxic exposure 
levels. (5,  65-67)  Studies  have suggested that  PIM  use  based  on level  of  kidney function is 
common, (7, 54, 68-76) but not always recognized, (7, 50, 54) with estimates as high as 62-67% 
in the inpatient and ambulatory seting. (72, 74) Moreover, medication resources for prescribers 
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often  present conflicting recommendations  on appropriate renal-based  dosing and 
contraindication, and have uncertain uptake in clinical practice. (9, 12-14, 77) Evaluating overal 
and specific  medication  use as  potentialy  modifiable risk factors that  might impact  health 
outcomes in older adults is critical. 
 
Several studies have evaluated the risk of hospitalization (57-60, 78) and death (55, 56, 61, 64, 
78-86) associated with polypharmacy and PIM use in older populations, but these studies were 
limited  by  homogenous samples, cross-sectional study  designs, lack  of information  on  kidney 
function,  or limited information  on the  use  of  over-the-counter  medications.  Therefore,  we 
characterized  baseline  medication  use across stages  of  kidney function in a community-based 
cohort of older adults, with a particular focus on medications deemed “potentialy inappropriate” 
based on kidney function or age, by any one of three commonly used drug references: the Beers 
criteria, the  Screening  Tool  of  Older  People’s  Prescriptions (STOPP) criteria, and 
Micromedex®. We then quantified the subsequent risk of hospitalization and death among those 
with baseline PIM use and polypharmacy, and assessed for diferences by CKD status.  
 
2.3 Methods 
2.3.1 Study population 
The  Atherosclerosis  Risk in  Communities (ARIC) study is a long-standing,  population-based, 
prospective cohort study of 15,792 adults folowed since 1987-1989.(87) In brief, ARIC study 
investigators recruited  participants  between  45 and  64  years  of age in the  United  States from 
Forsyth  County,  North  Carolina; Jackson,  Mississippi; suburban  Minneapolis,  Minnesota; and 
Washington  County,  Maryland.  For this  prospective analysis,  we included  participants  who 
atended  ARIC study  visit five (baseline  visit),  which took  place  between June,  2011, and 
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August, 2013 (N=6,544). We excluded participants without a serum creatinine measurement at 
visit five (n=96), those  with end-stage renal  disease as  defined  by registration in the  United 
States  Renal  Data  System (n=38), and  non-white/non-black  participants (n=18) leaving a total 
study population of 6,392 participants (Supplementary Figure S1A). ARIC had IRB approval 
at al study sites and participants gave informed consent at each visit. 
 
2.3.2 Measurement of kidney function and other covariates 
We  defined  kidney function  by a  participant’s estimated  glomerular filtration rate (eGFR).  We 
calculated eGFR  using serum creatinine (measured  by the  modified  kinetic Jafé  method), and 
the equation  developed  by the  Chronic  Kidney  Disease  Epidemiology  Colaboration.(88) We 
classified CKD into G-stages (G1= ≥90 mL/min/1.73m2; G2= 60-89 mL/min/1.73m2; G3a= 45-
59  mL/min/1.73m2;  G3b=  30-44  mL/min/1.73m2;  G4=  15-29  mL/min/1.73m2;  G5=  <15 
mL/min/1.73m2). (53) We also categorized participants by level of albuminuria using their urine 
albumin to  urine creatinine ratio (<30  mg/g,  30-300  mg/g,  >300  mg/g).  We  defined  CKD as 
eGFR <60 mL/min/1.73m2 at visit five, without regard to CKD duration or level of albuminuria. 
 
We defined diabetes melitus as a self-reported diabetes diagnosis, or the use of glucose lowering 
medications in the  previous  30  days, and  hypertension as a  blood  pressure  measure  of systolic 
>150 mm Hg and diastolic >90 mm Hg, or antihypertensive medication use during the previous 
30  days.  For  blood  pressure  measurement, a certified technician colected three seated 
measurements using a random-zero sphygmomanometer after 5 minutes of rest, and the mean of 
the second and third readings was used. We defined heart failure by self-reported or physician-
assessed  heart failure,  or  prior  physician-adjudicated  heart failure.  We  defined cardiovascular 
disease as prevalent coronary artery disease or stroke. We ascertained myocardial infraction (MI) 
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since  participants’ last  ARIC  visit  using self-report.  Similar to  other  ARIC investigations,(89) 
we  defined frailty  based  on five criteria including  weight loss, exhaustion, low energy 
expenditure, slowness, and  weakness; in this analysis,  pre-frail (1-2 criteria) and frail (>3 
criteria) were combined. We calculated the Charlson Comorbidity Index (CCI) (90, 91) based on 
data from  previous  hospitalizations  using abstracted  hospital records that  were  obtained from 
data linkages  with  hospitals in the  proximity  of  ARIC study sites,  or record requests from 
hospitals  outside  of those areas.  To ascertain cognitive functioning,  we  used the  Mini-Mental 
State  Examination (MMSE)  questionnaire score.  We  derived  body  mass index (BMI)  using 
weight (kilogram) and  height (meter)  measurements taken  during  physical examinations.  We 
also captured low-density lipoprotein (LDL) cholesterol,  high-density lipoprotein (HDL) 
cholesterol, and triglycerides from fasting  blood samples  drawn  during  physical examinations. 
Al  other  variables, such as sex, race, age, curent smoking status, and alcohol consumption 
(grams per week) were self-reported during a structured interview. Al definitions were based on 
information colected at participants’ visit five assessment. 
 
2.3.3 Medication use 
ARIC study staf captured  prescription and  over-the-counter (OTC)  medication  use, as  wel as 
vitamin and  dietary supplement  use, through structured interviews at  visit five.   Participants 
brought al medications and other products they had used in the prior 30 days to their study visit. 
If the  participant  did  not  bring their  medications, study staf folowed-up  over the  phone to 
colect these  data.  Study staf recorded a  maximum  of  25  products.  Thirty-eight  participants 
(0.6%) brought more than 25 products to their study visit; therefore, some product use on those 
participants  was  not colected.  For the  purpose  of the curent study,  we  did  not count  non-
injectable solutions, creams/lotions, and devices as medications, leaving 554 unique medications. 
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2.3.4 Medication references 
We categorized al 554 unique prescription and OTC oral, inhaled, or injectable medications by 
their drug grouping using the generic product identifier classification system. Since medication 
use information was obtained without regard to the method of atainment (prescription vs. OTC) 
or frequency of dosing (regular vs. as needed), we grouped al prescription and OTC nonsteroidal 
anti-inflammatory drugs (NSAIDs) into a combined NSAID category. We assessed medications 
in three commonly  used  drug references for  older adults:  American  Geriatrics  Society  Beers 
2015 criteria,(36)  Screening  Tool  of  Older  People’s  Prescriptions (STOPP)  version  2 
criteria,(92)  and  Truven  Health  Analytics  online  pharmacy reference  Micromedex®  1.0 
(Healthcare  Series; electronic  version;  Greenwood,  Colorado; accessed:  August,  2016).  We 
identified and cross-referenced medications that were contraindicated or recommended to avoid 
based  on  one’s  kidney function in any  of the three references.  We also identified and cross-
referenced medications that were contraindicated based on one’s age alone in Beers and STOPP 
only, as  Micromedex®  generaly references  Beers  or  STOPP criteria in its age-based 
recommendations. 
 
Many  medications in the  Beers and  Micromedex® references are  noted as contraindicated 
according to creatinine clearance or glomerular filtration rate that is not adjusted for body surface 
area. In these instances,  we converted the  participant’s eGFR to  unadjusted  units (mL/min)  by 
multiplying the eGFR (mL/min/1.73m2)  by their calculated  body surface area  divided  by  1.73, 
similar to other investigations. (93, 94) Where an absolute threshold was not explicitly stated but 
reference was made to avoid in “significant” or “severe” renal impairment, we a priori assumed 
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an eGFR threshold  of  <30  mL/min/1.73m2;  when  only “renal impairment”  was  noted,  <60 
mL/min/1.73m2 was used. 
 
2.3.5 Assessment of polypharmacy and PIM use 
We categorized polypharmacy using several categories of total number of prescription or OTC 
medications in the last  30  days, excluding the  use  of  other  products such as  vitamins and 
supplements:  0-3 medications,  4-5  medications,  6-9  medications, and  10  or  more  medications. 
We  defined  kidney-based  PIM  use as the  use  of a  medication that  was contraindicated  or 
recommended to avoid  based  on the  participant’s  kidney function in any  of the  medication 
references.  Because  dose information  was  not available,  PIM  use  based  on  dose  was  not 
assessed. We defined age-based PIM use as the use of a medication noted in Beers or STOPP as 
contraindicated in adults age  65  years  or  older; al  participants included in this study  were  65 
years  or  older.  We  did  not include contraindications  based  on two  or  more combined criteria 
such as contraindications  based  on  one’s age  plus an existing condition,  or the  use  of another 
medication concomitantly.  Where references  difered  with respect to  kidney function (i.e. 
Micromedex lists eGFR <45 mL/min/1.73 m2, and STOPP lists eGFR <30 mL/min/1.73m2 for 
the same  drug),  we  used the stricter criteria for analyses (i.e. eGFR  <45  mL/min/1.73m2). In 
addition, given that we did not have start dates or duration of use, the use of a medication (e.g. 
metformin)  was counted as  potentialy inappropriate in a  participant if a  drug reference 
recommended not starting the medication at their level of kidney function. 
 
2.3.6 Assessment of hospitalizations and death 
ARIC study staf  monitor and abstract  hospitalization  data for  ARIC cohort  members through 
data linkages  with local  hospitals in  proximity to each  of the four  ARIC sites;  hospitalizations 
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outside  of the community area are identified through semi-annual  participant reports, and 
subsequent record requests are  made to  obtain  data from those  hospitalizations. In this 
investigation, we included any hospitalization, regardless of the reason. Vital status was captured 
through linkages to the National Death Index. Participants’ observation time began at their visit 
five (baseline  visit/index  date), and  both  hospitalizations and  mortality  were assessed through 
December 31, 2014, or participants’ last known contact with study staf. 
 
2.3.7 Statistical analysis 
We calculated frequencies, means and proportions of cohort characteristics and medication use, 
including polypharmacy, kidney-based PIMs, and age-based PIMs, for al participants, stratified 
by CKD stage. We assessed trends across CKD G-stages in cohort characteristics, polypharmacy 
category, and mean number of medications and vitamins using logistic and linear regression for 
binary and continuous  variables, respectively, and an  ordinal  CKD  G-stage  variable.  We also 
used independent sample t-tests and two-sample tests of proportions to compare medication use 
between CKD and non-CKD participants. We tested for associations between mean number of 
medications and  CKD stage  using  univariable and  multivariable linear regressions.   We also 
tested for associations between PIM use and demographics, comorbidities, and total number of 
medications  using  univariable and  multivariable logistic regressions,  where  only covariates 
independently associated  with  PIM  use (p<0.05) in  univariable analyses  were included in the 
multivariable model. 
 
We calculated incidence rates for  hospitalization and  death  per  100  person-years in the ful 
cohort.  We  used  univariable and  multivariable zero-inflated  negative  binomial regression  with 
robust  variance estimators to calculate incidence rate ratios for  hospitalization comparing 
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categories  of  polypharmacy, and comparing those  with and  without  PIM  use, assessing for 
interactions between CKD status and both polypharmacy (categorical) and PIM use. We used a 
zero-inflated  model to account for frequent zero-value  observations and  over-dispersed  data. 
After assessing proportionality using a global test of Schoenfeld residuals, we performed similar 
analyses  using  Cox  proportional  hazards regression to evaluate associations  with al-cause 
mortality. In addition, to evaluate for non-linear associations between the number of medications 
(continuous) and each  of the  outcomes,  we  modeled total  number  of  medications as a cubic 
spline using four medications as the reference; we also assessed for interactions by CKD status. 
For  hospitalization and  death analyses,  we assessed age-based  PIM  use in the ful cohort, and 
kidney-based or combined kidney- and age-based PIM use among only those with CKD at visit 
five. In the later analyses, we did not include the use of aspirin-containing products as a kidney-
based PIM, since aspirin use was very common in the cohort.  
 
We adjusted al analyses for age, sex, race,  BMI, eGFR,  LDL cholesterol,  HDL cholesterol, 
triglycerides, smoking status, alcohol consumption,  MMSE score,  hypertension,  diabetes,  heart 
failure, cardiovascular disease, self-reported MI, CCI, frailty, and total vitamins/supplements. In 
PIM-based analyses,  we additionaly adjusted for  participants’ total  number  of  medications 
(continuous). 
 
Al analyses were done using Stata 14 (StataCorp, 2015; Colege, Station, TX).  
 
2.4 Results 
The study population was 58.7% female, 23.0% African American, and had a mean age of 76.3 
years (+5.2) (Table 1A). The majority had hypertension (69.8%), and 32.4%, 18.6%, 14.7% had 
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diabetes  melitus,  heart failure, and cardiovascular  disease, respectively.   The  mean  Charlson 
Comorbidity Index (CCI) was 4.2 (+1.8), and mean CCI was greater in higher CKD stages. The 
presence  of  CKD  was common,  with  29.1% (N=1,857)  of the cohort  having an eGFR  <60 
mL/min/1.73m2. Twenty-one percent had an albumin-to-creatinine ratio of 30 mg/g or higher.  
 
Antihypertensive  medications  were the  most commonly-used  medication  group (N=4,819, 
75.4%), with beta-blockers the most common antihypertensive class (N=2,141, 33.5%) (Figure 
1A).  Roughly  60% (N=2,859)  of those reporting antihypertensive  use took two  or  more 
antihypertensive  medications, and  25.4% (N=1,225) reported three  or  more (Supplementary 
Figure S2A). Lipid-lowering agents were also commonly reported (N=3,556, 55.6%), with over 
10% (N=373) using two or more lipid-lowering agents in the prior 30 days. The use of diabetes 
medications  was  not as common among  participants  overal (N=1,272,  19.9%),  but  many  of 
those reporting use of diabetes medicines reported using two or more such treatments (N=532, 
41.8%). As for analgesics, opioid medications were used in 10.5% (N=668) of participants, and 
of those, 8.4% (N=56) reporting using more than one opioid during the prior 30 days; the use of 
NSAID-containing (27.3%) and aspirin-containing (59.4%) products were much more common 
overal. The proportion of participants taking at least one medication within a medication class 
generaly increased  with  decreasing eGFR, except for  ACE inhibitors,  bisphosphonates, 
antidepressants, anxiolytic/hypnotic/sedatives, and aspirin-containing and  other  NSAID-
containing products (Figure 1A). Among participants who did not atend visit five, self-reported 
medication  use at their last  6-month  phone interview  was similar to those who  did atend  visit 
five (Supplementary Figure S3A). 
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On average,  participants reported  using  6.1 (+3.5)  medications and  2.3 (+2.2)  vitamins  or 
supplements.  Overal,  24.3% (N=1,553),  23.7% (N=1,518),  36.0% (N=2,302), and  15.9% 
(N=1,019)  of the cohort reported  using  0-3,  4-5,  6-9, and  10  or  more  prescription  or  OTC 
medications in the prior 30 days, respectively (Table 2A). More than 35% of participants used 
10  or  more  products  when the  use  of  medications,  vitamins, and supplements  were combined. 
Use of ten or more medications was more common among participants with CKD than without 
CKD (22.7%  versus  13.2%,  p<0.001).  Although  participants  with  CKD reported  using  more 
medications than those without CKD (7.0 versus 5.7, p<0.001), they used slightly fewer vitamins 
or supplements (2.1 versus 2.3, p<0.001).  
 
The association between higher CKD stage and greater number of medications used persisted in 
adjusted analyses. For example, participants with stage G4 or G5 took an average of 1.32 (95% 
confidence intervals [CI]: 0.73-1.90) more medications than those with stage G1 or G2 (Table 
2A). After adjustment, other corelates of greater numbers of medications included heart failure, 
cardiovascular  disease,  diabetes  melitus,  hypertension, self-reported previous  MI,  higher  CCI, 
frailty, female sex,  white race (compared to  African  American),  higher  BMI,  higher total 
numbers  of  vitamins/supplements,  higher triglycerides, lower  LDL cholesterol, and lower 
MMSE (Supplementary Table S1A).  
 
Age-based PIM use based on Beers and STOPP criteria occured in 31.3% (N=2,001) of the ful 
cohort (Supplementary  Table S2A), and  32.7% (N=608)  of the  participants  with  CKD.  The 
most common age-based  PIMs  were first-generation antihistamines,  benzodiazepines,  oral 
estrogens, and zolpidem.  In  univariable and  multivariable analyses, age-based  PIM  use  was 
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associated with higher total number of medications, CCI, female sex, and no diabetes melitus or 
hypertension (data not shown). 
 
Out of the 554 reported medications, 52 unique medications and 19 NSAID-containing products 
were identified as  potentialy inappropriate  based  on  kidney function in at least  one  of the 
references.  Kidney-based  PIM  use  was common among those in  CKD stage  G4  or  G5 (N=36, 
35.6%), and somewhat less common in those  with  CKD stage  G3a  or  G3b (N=223,  12.7%) 
(Table  3A).  The  most common  kidney-based  PIMs  were  metformin (N=42) and  NSAID-
containing  products (N=632).   Some  other commonly  used  kidney-based  PIMs included 
fenofibrate, spironolactone,  gabapentin, alendronate, and  hydrochlorothiazide-containing 
products.  Among  people  with  CKD,  kidney-based  PIM  use  was associated  with lower eGFR, 
higher total  number  of  medications, female sex, and  no self-reported  MI in  univariable and 
multivariable analyses (data not shown). 
 
Among the  6,379  participants  with  post-visit  5 folow-up,  median folow-up  was  2.6  years 
(interquartile range:  0.8  years).  There  were  4,178  hospitalizations in  2,197 cohort  members 
(34.4%)  over  16,111  person-years  of folow-up.  Overal, the incidence rate for  hospitalization 
was  26  per  100  person-years (Table  4A).  Hospitalization incidence increased  with  greater 
number of medications (15, 18, 29, and 49 per 100 person-years for 0-3, 4-5, 6-9, and 10 or more 
medications, respectively).  For each category  of  polypharmacy,  participants  with  CKD  had 
higher absolute risks  of  hospitalization than those  without  CKD;  however, there  were  no 
diferences in the relative risks  by  CKD status (al  p for interaction  >0.1). In the continuous 
analysis, there was a non-linear relationship between total number of medications and the risk of 
hospitalization (Figure  2A),  with  no statisticaly significant  diference  by  CKD status. 
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Compared to four medications, the use of five medications was associated with a 15% higher risk 
of  hospitalization (95%  CI:  7%-24%),  with increasing  numbers  of  medications associated  with 
increasing risk after five  medications.  With respect to  PIM  use, although those  with age- or 
kidney-based  PIM  use  had  higher  hospitalization rates than those without, these risks  did  not 
persist in adjusted analyses. 
 
There were 344 deaths during the folow-up period, with an incidence rate of 2 deaths per 100 
person-years (Table  4A).  Similar to  hospitalization, incidence  of  death increased  with  greater 
number of  medications (1,  1,  3, and  4  per  100  person-years for  0-3,  4-5,  6-9, and  10  or  more 
medications, respectively).   For each category  of  polypharmacy,  participants  with  CKD  had 
higher absolute risks of death than those without CKD; however, like hospitalization, there were 
no  diferences in the relative risks  by  CKD status (al  p for interaction  >0.1). In continuous 
analysis, there was a non-linear relationship between total number of medications and the risk of 
death (Figure 3A), with a suggestion of higher risk with less than four medications. There was 
no statisticaly significant  diference in the association  of total  number  of  medications and 
mortality  by  CKD status.  Compared to four  medications, the  use  of five and six  medications 
were  not associated  with increases in risk,  but seven  medications  was associated  with a  60% 
increase in the risk  of  death (95%  CI:  12%-128%),  with increasing  numbers  of  medications 
associated  with increasing  hazard ratios  until  plateauing after  11  medications.  Age- or  kidney-
based PIM use was not associated with death. 
 
2.5 Discussion 
In this community-based cohort of older adults, approximately one in six participants used 10 or 
more  medications, and  more than  one in three  used  10  or  more  products  when the  use  of 
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medications,  vitamins, and supplements  were combined.  Higher  numbers  of  medications  were 
more common among those  with lower eGFR, and  were associated  with  greater risks  of 
hospitalization and death. Age-based PIM and kidney-based PIM use were also common in the 
cohort, but were associated with hospitalization only in unadjusted analyses, and not associated 
with mortality risk. Our findings underscore the value of routine assessments of medication use 
among  older adults, and suggest that  minimizing  unnecessary  medication  use may  be an 
approach to reducing morbidity and mortality. 
 
Some  have  hypothesized that  polypharmacy  may  be a surogate  marker  of inappropriate 
medication use as it can increase the risk of adverse drug efects (ADEs), (6, 48)  and adverse 
drug-drug and drug-disease interactions. (8) A study by Onder et al (58) found that the primary 
risk factor for ADE-related hospitalization in older adults was polypharmacy. Other studies have 
assessed the risk of mortality in older adults with polypharmacy, and how various comorbidities 
diferentialy afect that risk. (55, 56, 61)  A recent study by Schötker et al (55) observed that 
those taking 10 or more medications with fewer concurent comorbidities had a higher relative 
risk  of  non-cancer  mortality than those  with  more concurent comorbidities.  We  hypothesized 
that the interaction  between  polypharmacy and comorbidities  might  be  driven in  part  by the 
presence of CKD, where ADEs are particularly common; (14, 95, 96) however, we found similar 
risk relationships associated in persons with and without CKD. 
 
An interesting finding from this study was the non-linear relationship between total number of 
medications and  mortality.  Our results suggested a  potentialy  higher  mortality risk among 
participants with fewer medications. Although not significant, the U-shaped association between 
total number of medications and mortality could represent medication underuse, but perhaps it is 
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more likely a result of residual confounding with providers reducing the number of medications 
in patients with poorer health status. Participants using higher numbers of medications generaly 
had a higher mortality risk, which may reflect a more severe disease phenotype.  
 
Surprisingly, both kidney- and age-based PIM use were not associated with adverse outcomes in 
our study. While prior studies have been somewhat equivocal with respect to these associations, 
our results  difer from those  which showed an increased risk in  morbidity and  mortality 
associated with PIM use. (64, 79-82) Our nul results suggest that the risks associated with PIM 
use in older adults may be minimal due to an increase in provider monitoring, or may be specific 
to certain  medications  used in specific clinical situations  not captured in a community-based 
cohort.  For example,  most  kidney-based  PIM  use  was  due to  metformin and  NSAIDs, and 
metformin  use at lower eGFRs is  now increasingly recognized as acceptable clinical  practice. 
There is also the  potential for channeling  bias,  whereby  only  healthy  or adherent  people  were 
prescribed  medications  deemed contraindicated, and in whom the  benefits  were considered to 
outweigh any apparent risks. It is also possible that using a “prevalent user” design selected out 
participants susceptible to the efects of PIM use, leaving only patients where these medications 
could  be tolerated.(64)  The  observed reductions in the reported  number  of  vitamins and 
supplements  with  decreasing levels  of  kidney function in this study suggest that  patients  may 
heed some provider warnings about PIM use; however, the high proportion of NSAID use seen 
in those with CKD runs counter to that suggestion. Regardless, coordinated prescribing and an 
increase in clinical assessments of common physiological changes as a result of aging, including 




One major impediment to preventing age- or kidney-based PIM use is the inconsistency between 
medication guidelines for older adult patients (77) and those with reduced kidney function. (9, 
13, 14) There is no gold standard reference with which to determine contraindication in either 
group, which can lead to confusion on appropriate prescribing. This can also lead to inconsistent 
findings  between studies  with  diferent  operationalized  definitions  of  PIM  use, and  may  be a 
reason why this and some other investigations have observed a nul result with respect to PIM 
use. (61,  78,  83-86)  In this analysis,  we found that the accessed  medication references  often 
varied in which drugs were contraindicated or recommended to avoid based on kidney function, 
used several diferent kidney function metrics, and in several instances, provided only qualitative 
guidelines without a specific level of kidney function noted. This lack of granularity may be a 
result of expansive exclusion criteria, such as older patients and those with CKD, in pre-market 
pharmacokinetic and safety studies.(16) In the absence of such data, recommendations may be 
quite subjective; moreover, medication resources often inconsistently report what data were used 
to formulate a recommendation.(9, 77)  
 
Our study  had several strengths.  The  ARIC cohort is a  wel-established cohort  of  older adults 
from several  geographicaly  diverse communities. Because cohort  members  have a 
comprehensive  physical exam at study  visits, rich clinical  data exist  on each  participant, 
including labs. Actual medication use was captured, rather than dispensed medications, and OTC 
medications, vitamins and supplements are also recorded.  
 
Our study also had several limitations. Analyses were limited to participants who atended visit 
five and may not include participants unable to atend based on their health status; however, for 
those  who  did  not atend, last reported  medication  use from  phone interviews  was similar to 
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those included in the study cohort. Because medication use was captured as any use in the prior 
30  days at a single  visit, contraindicated  drug-drug interactions and concurent  duplicate 
medication  use could  not  be assessed.  We could  not assess  PIM  use  with respect to  dosing as 
dose information  was  unavailable.  Medication  use  was captured through a  patient inventory at 
their study visit and was therefore dependent on the participant bringing in the medications, or 
self-reporting use in the prior 30 days. Few patients had eGFR <45 ml/min/1.73m2, and we had 
no information  on specialist care. If  medication  management  was  undertaken  by a  kidney 
specialist in those  with  more advanced  CKD,  medication-related adverse events  may  be 
mitigated, possibly contributing to the lack of efect modification by CKD status. As with any 
pharmacoepidemiologic investigation,  despite controling for  numerous confounders, residual 
confounding  by indication is  possible.  Finaly, this study  used a “prevalent  user”  design rather 
than assess risk after exposure initiation, therefore the  population  may lack  persons  who 
experienced adverse events early during polypharmacy or PIM use. 
 
2.6 Conclusions 
We found that  polypharmacy and  PIM  use  were relatively common in  older adults, and that 
higher numbers of medications were associated with higher risk of hospitalization and mortality. 
Unexpectedly,  while age- and  kidney-based  PIM  use  were common, they  were  not associated 
with  hospitalization  or  mortality after adjustment for  other covariates.   Although  CKD  was 
associated  with  higher absolute risk  of  hospitalization and  death across al categories  of 
medication use, the relative risk associated with greater number of medications was not diferent 
by CKD status. Greater coordination of care across providers may help to reduce the prevalence 
of polypharmacy and PIM use in populations who are particularly vulnerable to adverse events 
from medications.  
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2.7 Tables 
Table 1A: Study cohort demographic and baseline characteristics, stratified by level of kidney function 
 
Table 1A Key: Standard deviation (SD); estimated glomerular filtration rate (eGFR); high-density lipoproteins (HDL); low-density lipoproteins (LDL); Body 




G1: ≥90 G2: 60-89 G3a: 45-59 G3b: 30-44 G4: 15-29 G5: <15
Participants 6,392 571 (8.9%) 3,964 (62.0%)1,275 (19.9%) 481 (7.5%) 91 (1.4%) 10 (0.2%)
Mean age (SD) 76.3 (5.2) 73.2 (4.2) 75.9 (5.0) 77.8 (5.4) 78.9 (5.5) 79.1 (5.7) 78.6 (4.9) <0.001
Female 3,755 (58.7%) 362 (63.4%) 2,319 (58.5%) 736 (57.7%) 284 (59.0%) 46 (50.5%) 8 (80.0%) 0.11
Race
  White 4,919 (77.0%) 253 (44.3%) 3,223 (81.3%)1,016 (79.7%) 366 (76.1%) 59 (64.8%) 2 (20.0%) <0.001
 Black 1,473 (23.0%) 318 (55.7%) 741 (18.7%) 259 (20.3%) 115 (23.9%) 32 (35.2%) 8 (80.0%) <0.001
Body Mass Index (SD) 28.7 (5.8) 29.7 (7.1) 28.4 (5.5) 28.8 (5.5) 29.6 (6.0) 28.8 (6.1) 30.5 (6.6) 0.18
Current smoker 358 (5.6%) 54 (9.5%) 228 (5.8%) 49 (3.8%) 21 (4.4%) 6 (6.6%) 0 (0.0%) <0.001
Mean alcohol use (SD) 27.5 (64.1) 32.8 (93.2) 29.9 (64.6) 23.7 (52.9) 15.1 (42.9) 14.1 (43.5) 12.0 (37.9) <0.001
Mini-Mental State Examination (SD) 27.3 (3.1) 27.0 (3.1) 27.6 (2.9) 27.0 (3.3) 26.5 (3.4) 25.8 (4.8) 25.9 (2.1) <0.001
LDL cholesterol (SD) 2.7 (0.9) 2.8 (0.9) 2.7 (0.9) 2.7 (0.9) 2.5 (0.9) 2.5 (1.2) 2.2 (0.8) <0.001
HDL cholesterol (SD) 1.3 (0.4) 1.4 (0.4) 1.4 (0.4) 1.3 (0.4) 1.2 (0.3) 1.2 (0.4) 1.1 (0.3) <0.001
Triglycerides (SD) 1.4 (0.7) 1.2 (0.5) 1.4 (0.7) 1.5 (0.7) 1.6 (0.9) 1.5 (0.9) 1.4 (0.8) <0.001
Albuminuria (n=5,683) (n=495) (n=3,480) (n=1,173) (n=440) (n=86) (n=9)
   <30 mg/g 4,488 (79.0%) 410 (82.8%) 2,913 (83.7%) 884 (75.4%) 253 (57.5%) 28 (32.6%) 0 (0.0%) <0.001
   30-300 mg/g 1,035 (18.2%) 79 (16.0%) 515 (14.8%) 251 (21.4%) 151 (34.3%) 34 (39.5%) 5 (55.6%) <0.001
   >300 mg/g 160 (2.8%) 6 (1.2%) 52 (1.5%) 38 (3.2%) 36 (8.2%) 24 (27.9%) 4 (44.4%) <0.001
Comorbidities
   Charlson Comorbidity Index (SD) 4.2 (1.8) 3.7 (1.7) 4.0 (1.6) 4.6 (2.0) 5.4 (2.3) 6.1 (2.6) 7.6 (3.7) <0.001
   Hypertension 4,461 (69.8%) 403 (70.6%) 2,579 (65.1%) 978 (76.7%) 410 (85.2%) 81 (89.0%) 10 (100.0%) <0.001
   Diabetes 2,072 (32.4%) 205 (35.9%) 1,153 (29.1%) 436 (34.2%) 224 (46.6%) 49 (53.8%) 5 (50.0%) <0.001
   Hypertension and diabetes 1,706 (26.7%) 171 (29.9%) 912 (23.0%) 371 (29.1%) 201 (41.8%) 46 (50.5%) 5 (50.0%) <0.001
   Heart Failure 1,191 (18.6%) 103 (18.0%) 594 (15.0%) 282 (22.1%) 164 (34.1%) 41 (45.1%) 7 (70.0%) <0.001
   Cardiovascular disease 940 (14.7%) 44 (7.7%) 500 (12.6%) 233 (18.3%) 133 (27.7%) 26 (28.6%) 4 (40.0%) <0.001
  Self-reported myocardial infarction 486 (7.6%) 26 (4.6%) 248 (6.3%) 125 (9.8%) 69 (14.3%) 16 (17.6%) 2 (20.0%) <0.001
   Frailty 3,132 (49.0%) 289 (50.6%) 1,847 (46.6%) 643 (50.4%) 292 (60.7%) 55 (60.4%) 6 (60.0%) <0.001
Overal




Table 2A: Association between reported number of medications and vitamins/supplements and chronic kidney disease stage 
 
a linear model: average number of additional medications relative to reference [95% confidence interval (CI)]; constant = 5.72 (CI: 4.09-7.36) medications 
 
Table 2A Key: Standard deviation (SD); estimated glomerular filtration rate (eGFR); Fuly adjusted model was adjusted for hypertension, cardiovascular disease, 










G1/G2: ≥60 (n=4,535) G3a: 45-59 (n=1,275) G3b: 30-44 (n=481) G4/G5: <30 (n=101)
ref 0.81 (0.59-1.02) 2.07 (1.75-2.40) 3.16 (2.48-3.84)









Total medications only (Continuous)
a
40 (39.6%)
Proportion reporting ≥10 combined medications 
and vitamins/supplements
2,272 (35.5%) 1,488 (32.8%) 495 (38.8%) 227 (47.2%) 62 (61.4%)
Proportion reporting ≥10 medications 1,019 (15.9%) 597 (13.2%) 240 (18.8%) 142 (29.4%) <0.001
<0.001
<0.00111 (10.9%)50 (10.4%)243 (19.1%)1,249 (27.5%)
<0.001
1.7 (1.6)
Number of combined medications and vitamins/ 
supplements (mean and SD)
8.4 (4.3) 8.1 (4.3) 8.7 (4.3) 9.8 (4.5)
Number of vitamins/ supplements (mean and SD) 2.3 (2.2) 2.3 (2.3) 2.1 (2.1) 2.0 (2.0)
10.6 (4.7)
Overal         
(n=6,392)
Chronic kidney disease stage: eGFR (mL/min/1.73m2)
Number of medications (mean and SD) 6.1 (3.5) 5.7 (3.4) 6.5 (3.5) 7.8 (3.8) 8.9 (4.3)
Proportion reporting 0-3 medications
40 (39.6%)Proportion reporting 6-9 medications 2,302 (36.0%) 1,546 (34.1%) 501 (39.3%) 215 (44.7%)
Proportion reporting 4-5 medications 74 (15.4%) 10 (9.9%)
1,553 (24.3%)
1,518 (23.7%) 1,143 (25.2%) 291 (22.8%)
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Table 3A: Prevalence of kidney-based potentialy inappropriate medication use by chronic kidney disease stage 
 
 
G1: ≥90 G2: 60-89 G3a/b: 30-59 G4/5: <30
Micromedex eGFR <45 mL/min/1.73m2 42
STOPP eGFR <30 mL/min/1.73m
2
4
3 (0.5%) 10 (0.3%) 2 (0.1%) 0 Micromedex eGFR <45 mL/min/1.73m
2 15 (0.2%) 0
0 5 (0.1%) 3 (0.2%) 0 Micromedex eGFR <45 mL/min/1.73m
2 8 (0.1%) 2
0 6 (0.2%) 6 (0.3%) 0 Micromedex eGFR <45 mL/min/1.73m
2 12 (0.2%) 1
2 (0.4%) 0 0 1 (1.0%) Micromedex SCr >2.0 mg/dL 3 (0.1%) 1
1 (0.2%) 2 (0.1%) 0 0 Micromedex CrCl <30 mL/min 3 (0.1%) 0
5 (0.9%) 58 (1.5%) 73 (4.2%) 6 (5.9%) Micromedex Severe renal impairment 142 (2.2%) 6
4 (0.7%) 44 (1.1%) 31 (1.8%) 1 (1.0%) Micromedex Severe renal impairment 80 (1.3%) 1
0 1 (0.0%) 0 0 Micromedex CrCl <50 mL/min 1 (0.0%) 0
13 (2.3%) 162 (4.1%) 127 (7.2%) 3 (3.0%) Micromedex Significant renal impairment 305 (4.8%) 3
44 (7.7%) 197 (5.0%) 106 (6.0%) 1 (1.0%) Micromedex eGFR <30 mL/min/1.73m
2 348 (5.4%) 1
Micromedex CrCl <50 mL/min 0
Beers CrCl <30 mL/min 0
Micromedex SCr >2.5 mg/dL 0
Beers CrCl <30 mL/min 0
2 (0.4%) 23 (0.6%) 14 (0.8%) 0 Micromedex SCr >2.5 mg/dL 39 (0.6%) 0
69 (12.0%) 497 (12.5%) 249 (14.2%) 10 (9.9%) Micromedex SCr >2.5 mg/dL 825 (12.9%) 2
0 0 1 (0.1%) 0 Micromedex GFR <10 mL/min 1 (0.0%) 0
0 3 (0.1%) 2 (0.1%) 0 Micromedex CrCl <30 mL/min 5 (0.1%) 0
Micromedex GFR <10 mL/min 0
Beers CrCl <30 mL/min 6
0 1 (0.0%) 0 0 Micromedex GFR <60 mL/min 1 (0.0%) 0
2 (0.4%) 2 (0.1%) 1 (0.1%) 0 Micromedex CrCl <30 mL/min 5 (0.1%) 0
9 (1.6%) 57 (1.4%) 29 (1.7%) 0 Micromedex CrCl <30 mL/min 95 (1.5%) 0
0 1 (0.0%) 0 0 Micromedex CrCl <30 mL/min 1 (0.0%) 0

















Triamterene 0 1 (0.0%) 0 0 1 (0.0%)
Cardiovascular agents
Diuretic (loop and thiazide)
Triamterene-hydrochlorothiazide
Lisinopril-hydrochlorothiazide












Chronic kidney disease stage: eGFR
Reference Criteria Overal use PIM use
Metabolic agents
Diabetes medication
Metformin 99 (17.3%) 437 (11.0%) 175 (10.0%) 4 (4.0%) 715 (11.2%)
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G1: ≥90 G2: 60-89 G3a/b: 30-59 G4/5: <30
1 (0.2%) 13 (0.3%) 3 (0.2%) 0 Micromedex CrCl <60 mL/min 17 (0.3%) 2
0 1 (0.0%) 1 (0.1%) 0 Micromedex CrCl <30 mL/min 2 (0.0%) 0
0 4 (0.1%) 4 (0.2%) 1 (1.0%) Micromedex CrCl <15mL/min 9 (0.1%) 0
2 (0.4%) 22 (0.6%) 21 (1.2%) 2 (2.0%) Micromedex CrCl <15mL/min 47 (0.7%) 0
Miscelaneous
0 2 (0.1%) 0 0 Micromedex Renal impairment 2 (0.0%) 0
2 (0.4%) 2 (0.1%) 1 (0.1%) 0 Micromedex Severe renal impairment 5 (0.1%) 0
3 (0.5%) 6 (0.2%) 3 (0.2%) 0 Micromedex GFR <50 mL/min 12 (0.2%) 2
3 (0.5%) 5 (0.1%) 6 (0.3%) 0 Micromedex Severe renal impairment 14 (0.2%) 0
34 (6.0%) 169 (4.3%) 113 (6.4%) 12 (11.9%)Micromedex CrCl <30 mL/min 328 (5.1%) 7
0 3 (0.1%) 0 0 Micromedex CrCl <10 mL/min 3 (0.1%) 0
0 3 (0.1%) 2 (0.1%) 0 Micromedex CrCl <9 mL/min 5 (0.1%) 0
Micromedex Many depending on product N/A
STOPP eGFR <50 mL/min/1.73m2 632
Beers CrCl <30 mL/min 49
Micromedex Many depending on product N/A
STOPP eGFR <50 mL/min/1.73m
2
194
Beers CrCl <30 mL/min 8
2 (0.4%) 29 (0.7%) 8 (0.5%) 1 (1.0%) Micromedex CrCl <30 mL/min 40 (0.6%) 1
0 0 1 (0.1%) 0 Micromedex CrCl <30 mL/min 1 (0.0%) 0
2 (0.4%) 20 (0.5%) 4 (0.2%) 0 Micromedex Severe renal impairment 26 (0.4%) 0
Micromedex CrCl <30 mL/min 2
Beers CrCl <30 mL/min 2
62 (1.0%)
Buspirone





NSAIDs                                 
(excluding aspirin containing products)
188 (32.9%)1,127 (28.4%) 417 (23.7%) 11 (10.9%) 1,743 (27.3%)
Alzheimer's/dementia
Galantamine

















Chronic kidney disease stage: eGFR
Reference Criteria Overal use
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Table 3A: Continued 
 
 
* Micromedex does note that below an eGFR of 30 mL/min/1.73m2, the use of metformin is contraindicated, but Micromedex also notes that patients should not 
be started on metformin if their eGFR is under 45 mL/min/1.73m2, and that if their eGFR fals below 45 mL/min/1.73m2 “risks and benefits of continued use 
should be considered” (Glucophage; metformin HCl; oral tablet; 2017). 
 
Table 3A Key: Potentialy inappropriate medication (PIM); creatinine clearance (CrCl); estimated glomerular filtration rate (eGFR); glomerular filtration rate 
(GFR); Serum creatinine (SCr); Nonsteroidal anti-inflammatory drug (NSAID); Criteria column is the kidney function threshold where medication use is to be 
avoided;  Qualitative criteria such as “significant”  or “severe” renal impairment  were categorized as eGFR  <30  mL/min/1.73m2, and “renal impairment”  was 




G1: ≥90 G2: 60-89 G3a/b: 30-59 G4/5: <30
0 2 (0.05%) 1 (0.06%) 0 Micromedex CrCl <30 mL/min 3 (0.05%) 0
9 (1.6%) 30 (0.8%) 29 (1.7%) 1 (1.0%) Micromedex CrCl <10 mL/min 69 (1.1%) 0
22 (3.9%) 144 (3.6%) 59 (3.4%) 2 (2.0%) Micromedex CrCl <35 mL/min 227 (3.5%) 9
1 (0.2%) 14 (0.4%) 6 (0.3%) 0 Micromedex CrCl <30 mL/min 21 (0.3%) 0
3 (0.5%) 17 (0.4%) 13 (0.7%) 0 Micromedex CrCl <30 mL/min 33 (0.5%) 0
0 4 (0.1%) 3 (0.2%) 0 Micromedex CrCl <35 mL/min 7 (0.1%) 0
1 (0.1%) 5 (0.1%) 1 (0.1%) 0 Micromedex CrCl <30 mL/min 7 (0.1%) 0
0 1 (0.0%) 0 0 Micromedex Renal impairment 1 (0.0%) 0
Micromedex CrCl <30 mL/min 0
Beers CrCl <30 mL/min 0
STOPP eGFR <15 mL/min/1.73m2 0
Beers CrCl <30 mL/min 0
STOPP eGFR <30 mL/min/1.73m
2
0
10 (1.7%) 22 (0.6%) 14 (0.8%) 2 (2.0%) Micromedex CrCl <10 mL/min 48 (0.8%) 0
Hyperuricemia agents
1 (0.2%) 4 (0.1%) 4 (0.2%) 0 Beers CrCl <30 mL/min 9 (0.1%) 0
6 (1.1%) 21 (0.5%) 44 (2.5%) 5 (5.0%) STOPP eGFR <10 mL/min/1.73m2 76 (1.2%) 1








Dabigatran 2 (0.4%) 23 (0.6%) 14 (0.8%) 0 39 (0.6%)
Fondaparinux 0 0 1 (0.1%) 0 1 (0.0%)
Silodosin
















Chronic kidney disease stage: eGFR
Reference Criteria Overal use
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Table 4A: Incidence rate ratios and hazard ratios for hospitalization and death, respectively, by polypharmacy and PIM use 
 
a Some  participants  had  multiple  hospitalizations  during folow-up b Polypharmacy (categorical) and  CKD status interaction  not statisticaly significant         
c Includes participants with CKD only (eGFR <60 mL/min/1.73m2) *=p<0.05 
Table 4A Key: Potentialy inappropriate medication (PIM); Chronic kidney disease (CKD); Incidence rate ratio (IRR); Hazard ratio (HR); Person years (PYs); 
estimated glomerular filtration rate (eGFR); Model was adjusted for estimated glomerular filtration rate, hypertension, cardiovascular disease, diabetes, heart 
failure, self-reported myocardial infarction, Charlson Comorbidity Index, frailty, sex, age, race, Body Mass Index, curent smoking status, curent alcohol use, 
Mini-Mental State Evaluation, high-density lipoproteins, low-density lipoproteins, triglycerides, and total vitamins/supplements. PIM use analyses were 
additionaly adjusted by total number of medications (continuous).
Overal incidence rate
Hospitalizations Incidence rate Unadjusted IRR Adjusted IRR Deaths Incidence rate Unadjusted HR Adjusted HR
Polypharmacy (overal)
0-3 medications 607 15 per 100 PYs 0.85 (0.73-0.99)* 0.91 (0.78-1.06) 53 1 per 100 PYs 1.07 (0.72-1.58) 1.17 (0.78-1.76)
4-5 medications 702 18 per 100 PYs ref ref 48 1 per 100 PYs ref ref
6-9 medications 1,664 29 per 100 PYs 1.67 (1.46-1.91)* 1.37 (1.20-1.55)* 141 3 per 100 PYs 1.99 (1.44-2.77)* 1.65 (1.16-2.35)*
10+ medications 1,205 49 per 100 PYs 2.88 (2.48-3.34)* 1.93 (1.64-2.27)* 102 4 per 100 PYs 3.42 (2.43-4.82)* 2.40 (1.60-3.59)*
Polypharmacy by CKD statusb
CKD
0-3 medications 188 25 per 100 PYs 1.10 (0.80-1.50) 1.13 (0.84-1.52) 20 3 per 100 PYs 1.37 (0.71-2.62) 1.57 (0.81-3.03)
4-5 medications 214 23 per 100 PYs ref ref 17 2 per 100 PYs ref ref
6-9 medications 705 39 per 100 PYs 1.76 (1.37-2.27)* 1.45 (1.14-1.84)* 73 4 per 100 PYs 2.19 (1.29-3.69)* 1.91 (1.11-3.28)*
10+ medications 558 57 per 100 PYs 2.60 (1.98-3.40)* 1.85 (1.38-2.48)* 55 6 per 100 PYs 3.12 (1.81-5.37)* 2.58 (1.45-4.60)*
No CKD
0-3 medications 419 13 per 100 PYs 0.80 (0.67-0.95)* 0.85 (0.71-1.01) 33 1 per 100 PYs 0.99 (0.61-1.61) 1.01 (0.61-1.68)
4-5 medications 488 16 per 100 PYs ref ref 31 1 per 100 PYs ref ref
6-9 medications 959 25 per 100 PYs 1.53 (1.31-1.79)* 1.33 (1.14-1.55)* 68 2 per 100 PYs 1.66 (1.09-2.55)* 1.51 (0.95-2.38)
10+ medications 647 44 per 100 PYs 2.81 (2.35-3.38)* 2.01 (1.68-2.41)* 47 3 per 100 PYs 3.09 (1.97-4.87)* 2.40 (1.43-4.05)*
PIM use
   Age-based PIM
No 2,663 24 per 100 PYs ref ref 223 2 per 100 PYs ref ref
Yes 1,515 30 per 100 PYs 1.28 (1.15-1.43)* 0.98 (0.88-1.09) 121 2 per 100 PYs 1.23 (0.99-1.54) 1.13 (0.88-1.46)
   Kidney-based PIMc
No 1,576 37 per 100 PYs ref ref 162 4 per 100 PYs ref ref
Yes 791 49 per 100 PYs 1.46 (1.17-1.81)* 1.15 (0.91-1.45) 80 5 per 100 PYs 1.19 (0.78-1.80) 0.97 (0.59-1.58)
   Age- or kidney-based PIMc
No 1,291 38 per 100 PYs ref ref 137 4 per 100 PYs ref ref
Yes 1,076 43 per 100 PYs 1.32 (1.11-1.56)* 1.05 (0.89-1.24) 105 4 per 100 PYs 1.26 (0.93-1.72) 1.28 (0.91-1.79)
2 per 100 PYs26 per 100 PYs
Death (N=344) among ful cohortHospitalizations (N=4,178)a among 2,197 participants
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* = statisticaly significant (p<0.05)  
a Constant = 5.72 (4.09-7.36) 
 
Supplementary Table  S1A Key:  Fuly adjusted linear  model  was identical to linear  model in table  2, adjusted for 
CKD stage,  hypertension, cardiovascular  disease,  diabetes,  heart failure, self-reported  myocardial infraction, 
Charlson  Comorbidity Index (continuous), frailty, sex, race,  Body  Mass Index (BMI) (continuous; rounded to 
nearest  whole  number), curent smoking status, curent alcohol  use (continuous; rounded to  nearest  gram), age 
(continuous; rounded to  nearest  whole  number),  Mini-Mental  State  Examination (MMSE) (continuous),  high-
density lipoproteins (HDL) (continuous; rounded to the nearest tenth), low-density lipoproteins (LDL) (continuous; 
rounded to the  nearest tenth), triglycerides (continuous; rounded to the  nearest tenth), and total  number  of 

















Heart failure 2.57 (2.36 - 2.78)* 1.17 (0.97 - 1.38)*
Cardiovascular disease 2.28 (2.04 - 2.52)* 0.75 (0.50 - 0.99)*
Diabetes 2.47 (2.29 - 2.64)* 1.18 (1.01 - 1.35)*
Hypertension 2.39 (2.21 - 2.57)* 1.46 (1.30 - 1.63)*
Self-reported myocardial infarction 2.34 (2.02 - 2.66)* 0.12 (-0.19 - 0.44)
Charlson Comorbidity Index (per point) 0.60 (0.55 - 0.64)* 0.31 (0.26 - 0.36)*
Frailty 0.84 (0.67 - 1.01)* 0.30 (0.16 - 0.45)*
Alcohol use (per gram per week) 0.00 (-0.01 - 0.00) 0.00 (-0.00 - 0.00)
Current smoker -0.36 (-0.74 - 0.02) -0.17 (-0.49 - 0.14)
Female 0.43 (0.26 - 0.61)* 0.77 (0.60 - 0.94)*
White -0.22 (-0.42 - -0.01)* 0.39 (0.19 - 0.58)*
BMI (per 1 kg/m2) 0.14 (0.12 - 0.15)* 0.06 (0.05 - 0.07)*
Age (per year) 0.04 (0.02 - 0.05)* -0.04 (-0.06 - -0.03)*
MMSE (per point) -0.07 (-0.10 - -0.05)*-0.04 (-0.06 - -0.01)*
Triglycerides (per 0.1 mmol/L) 0.60 (0.48 - 0.72)* 0.32 (0.19 - 0.45)*
HDL cholesterol (per 0.1 mmol/L) -1.40 (-1.63 - -1.16)* 0.18 (-0.08 - 0.43)
LDL cholesterol (per 0.1 mmol/L) -1.18 (-1.27 - -1.09)*-0.79 (-0.87 - -0.70)*
Vitamins/supplements (per additional vitamin) 0.13 (0.09 - 0.17)* 0.18 (0.15 - 0.21)*
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Supplementary Table S2A key: Nonsteroidal anti-inflammatory drug (NSAID); note al criteria were based on 
medication use after 65 years old. Reference noted above is the reference with the most restrictive criteria (i.e. any 
use contraindicated), as opposed to contraindication based on comorbid conditions or concurent use with another 




Glyburide Beers 107 (1.7%)
Endocrine-metabolic
Megestrol Beers 8 (0.1%)
Estrogens (oral) Beers 172 (2.7%)
Desiccated thyroid extract Beers 2 (0.0%)
Cardiovasuclar agents
Antiarrhythmic
Disopyramide Beers 1 (0.0%)
Alpha adrenergic agonist
Guanfacine Beers 12 (0.2%)
Methyldopa Beers 5 (0.1%)
Anticholinergic
Hyoscyamine Beers 14 (0.2%)
Propantheline Beers 1 (0.0%)
Dicyclomine Beers 40 (0.6%)
Clidinium/chlordiazepoxide Beers 14 (0.2%)
Antiemetic
Dimenhydrinate Beers 6 (0.1%)
Meclizine Beers 104 (1.6%)
Scopolamine Beers 1 (0.0%)
Antibiotic
Nitrofurantoin macrocrystaline Beers 17 (0.3%)
Central nervous system agents
Anxiolytic
Meprobamate Beers 2 (0.0%)
Antidepressant
Paroxetine Beers 80 (1.2%)
Desipramine Beers 1 (0.0%)
Doxepin Beers 14 (0.2%)
Imipramine Beers 13 (0.2%)
Nortriptyline Beers 36 (0.6%)
Barbituate
Butabarbital Beers 2 (0.0%)
Phenobarbital Beers 6 (0.1%)
Hypnotic
Eszopiclone Beers/STOPP 7 (0.1%)
Zaleplon Beers/STOPP 4 (0.1%)
Zolpidem Beers/STOPP 166 (2.6%)
NSAID
Ketorolac tromethamine Beers 3 (0.0%)
Antiparkinsonian
Benztropine mesylate Beers 3 (0.0%)
Trihexyphenidyl Beers 3 (0.0%)
Skeletal muscle relaxant
Carisoprodol Beers 6 (0.1%)
Chlorzoxazone Beers 2 (0.0%)
Cyclobenzaprine Beers 105 (1.6%)
Metaxalone Beers 14 (0.2%)
Methocarbamol Beers 17 (0.3%)
Analgesic
Meperidine Beers 1 (0.0%)
Anticoagulant
Dipyridamole Beers 7 (0.1%)
Containing multiple products
1st generation antihistamines Beers/STOPP 779 (12.2%)
Benzodiazepines Beers/STOPP 545 (8.5%)
Antipsychotics STOPP 66 (1.0%)
Amitriptyline-containing Beers 117 (1.8%)
Atropine-containing Beers 20 (0.3%)













eGFR 60 or higher (n=4,535)
eGFR 30 to 59 (n=1,756)






































































































































5,043 died before visit 5
4205 refused or were unable to atend
96 had no visit 5 serum creatinine
































Did not atend (N=2,326)
Did atend (N=6,392)
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3 Spironolactone  use among  patients  with  heart failure across the 
spectrum of kidney function 
 
3.1 Abstract 
Background: Spironolactone, efective in reducing  morbidity and  mortality in heart failure 
(HF), is  not recommended in those  with reduced  kidney function.  This study characterized 
spironolactone initiation among patients with HF, and evaluated diferential initiation by kidney 
function. 
Methods: We included  patients  with incident  HF and available laboratory  data in the 
MarketScan  Commercial  Claims database (MS) from  2010-2015, and the  Geisinger  Health 
System Integrated Electronic Health Record (GS) from 2004-2016. We assessed spironolactone 
use through  prescription  orders and  dispensing, and  used  Cox  proportional  hazards regression 
models to identify patient characteristics associated with spironolactone initiation. 
Results: Among 22,956 patients in MS, the mean age was 54.3 (+8.7) years, 47.2% were female, 
and the mean estimated glomerular filtration rate (eGFR) was 79.2 (+21.5) ml/min/1.73m2. The 
16,547 patients in GS were older (74.1 years +12.9), more often female (51.7%), and had a lower 
mean eGFR (62.4 +24.3).  There  were  1,398 initiators  of spironolactone (3.5  per  1,000  person-
months [PM]) in  MS, and  1,747 initiators (3.1  per  1,000  PM) in  GS;  7.0% and  9.9% initiated 
within two years in MS and GS, respectively. In adjusted models, patients with eGFR <30 were 
less likely to initiate than  patients  with eGFR  60-89 (meta-analyzed  hazard ratio:  0.61,  95% 
confidence interval:  0.44-0.83); there  were  no  diferences  between any  other eGFR category. 
Loop diuretic use and lower serum potassium (<3.5, compared to 3.5-4.9) were associated with 
greater likelihood of initiation. 
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Conclusion: Fewer than  one in ten  patients  with  HF initiated spironolactone  over two years. 
Initiation was least likely among those with the lowest renal function. 
 
3.2 Introduction 
Heart failure (HF) is common and causes substantial  morbidity,  with roughly  half  of  patients 
dying within five years of their initial diagnosis.(97) Chronic kidney disease (CKD) is prevalent 
among patients with HF, and can further complicate treatment options for patients with already 
complex and evolving medical needs. While several treatments, such as aldosterone antagonists, 
angiotensin-converting enzyme inhibitors (ACEi), and angiotensin I receptor  blockers (ARB), 
may reduce  morbidity and  mortality among  patients  with  HF, these  medications can impact 
potassium homeostasis, increasing the risk of hyperkalemia. 
 
Spironolactone, an aldosterone antagonist indicated for the treatment of severe heart failure with 
reduced ejection fraction (HFrEF),(19) has  been shown to  be efective in reducing repeat 
hospitalization and  mortality.(24,  25,  34,  41,  98) While  American  Heart  Association (AHA) 
guidelines recommend aldosterone antagonists in these  patients (99,  100) as  wel as 
“appropriately selected”  heart failure  patients  with  preserved ejection fraction (HFpEF), they 
recommend against use in  patients  with an estimated  glomerular filtration rate (eGFR) <30 
ml/min/1.73 m2 due to concerns for hyperkalemia. Nevertheless, several ongoing trials sponsored 
by mix of government and industry sponsors (101) are evaluating spironolactone in patients with 
CKD, including those with end-stage kidney disease. Previously published cross-sectional study 
data suggest that the  use  of aldosterone antagonists is limited in  patients  with  HF and reduced 
kidney function, but highly variable across hospital systems; however, this could also be true of 
patients with normal kidney function. (44, 102) 
 41 
 
Patients with HF and CKD may benefit from spironolactone,(29, 103) but litle is known about 
its actual  use in this  higher-risk  population,  or the extent to  which  patients’  kidney function 
impacts the likelihood of spironolactone initiation in the context of other common comorbidities 
and concomitant medications. Given the uncertainty in its use among patients with lower eGFR, 
we examined the  prevalence and corelates  of spironolactone initiation, and  discontinuation 
among initiators, in two large, diverse cohorts of patients with incident HF in the United States. 
 
3.3 Methods 
3.3.1 Study design and data sources 
We  used  patient-level  data from two large electronic  health  databases:  Truven  MarketScan 
Commercial Claims and Encounters database (MarketScan) and Electronic Health Record (EHR) 
data from the  Geisinger  Health  System (Geisinger) in  Pennsylvania,  United  States (U.S.).   For 
MarketScan analyses,  we  used  paid  health care encounter claims from employer-sponsored 
insurance  providers for  patients  not eligible for  Medicare (<65  years  old), including 
administrative claims related to medication dispensing, and inpatient, outpatient, and laboratory 
encounters from  2010 through  2015.   Of  note,  MarketScan’s laboratory  data  only includes 
patients  whose insurance  providers  have contracts  with large central labs (e.g.  Quest 
Diagnostics).  For  Geisinger analyses,  we  used  EHR  data from  2004 through 2016, including 
inpatient, outpatient, and laboratory data for patients receiving primary care at Geisinger; linkage 
with the United States Renal Data System (USRDS) was used to obtain end-stage renal disease 
(ESRD) status for exclusion.  Medication  data at  Geisinger  were captured from  medication 
orders, and  medication reconciliation during  health care encounters.  Analyses  were conducted 
separately in each database. 
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3.3.2 Population 
We included patients age 18 years or older with incident International Classification of Diseases, 
9th  Revision,  Clinical  Modification (ICD-9-CM)  or ICD-10  diagnosis codes indicating  HF 
(Supplementary Table  S1B) from inpatient  or  outpatient records, and at least  one available 
serum creatinine (SCr) and  potassium (K) labs, and  medication  data (N=66,869 from 
MarketScan; N=32,536 from Geisinger). In most patients (~65%), the incident HF code was for 
unspecified HF (Supplementary Table S2B). 
 
We excluded patients with ESRD, defined by ICD-9/10 diagnosis or procedure codes or USRDS 
registry, those  with less than  90  days  of available lookback in the  data, those  with any 
spironolactone  use prior to their incident  HF code  date, and  patients  without an available 
outpatient SCr or K measured within 180 days before or seven days after their incident HF code 
date, leaving a total study  population  of  22,956 in  MarketScan, and  16,547 in  Geisinger 
(Supplementary Figure S1B). 
 
3.3.3 Exposure 
Using a six-month  window (180  days)  before the  HF index  date to  up to seven  days after,  we 
selected  baseline eGFR and  K as the closest  measurement to the index  date (Supplementary 
Figure  S2B).  We  defined eGFR  based  on  outpatient  SCr and the  Chronic  Kidney Disease 
Epidemiology  Colaboration (CKD-EPI) equation.(88) MarketScan  data  does  not  have 
information  on race, an input in the  CKD-EPI equation; therefore, al  MarketScan  participants 
were considered  non-black for estimating eGFR  which  would  bias  African-American  patients 
eGFR roughly 15% lower than expected. We classified eGFR using four primary categories (≥90 
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mL/min/1.73m2;  89-60  mL/min/1.73m2;  59-30  mL/min/1.73m2;  <30  mL/min/1.73m2).  We 
classified potassium levels using three categories (<3.5 mEq/L; 3.5-4.9 mEq/L; >5.0 mEq/L). 
 
3.3.4 Outcomes 
Patients were folowed from their index date until incident spironolactone use, or administrative 
censoring,  which  we  defined as an individuals’ last recorded  health care encounter  date 
(inpatient, outpatient, laboratory, or medication order), death (for Geisinger only) or the end date 
of the study  period (December  31st,  2015 for  MarketScan, and  December  31st,  2016, for 
Geisinger), whichever came first. We defined the primary outcome of interest, incident initiation 
of any spironolactone  product (single-ingredient  or spironolactone-hydrochlorothiazide 
combination  products), as the first recorded spironolactone  product  dispensing claim  or 
medication order, among those with no prior claims or orders for spironolactone products in the 
MarketScan or Geisinger data, respectively.  For discontinuation analyses, we defined duration 
of spironolactone use as continuous use after initiation, alowing for a 60-day gap between the 
end of one prescription and the start of the next. We defined discontinuation as the last date of 
continuous spironolactone coverage  noted in the  prescription claims  or  medical record among 




We used administrative files to capture demographic data and, for MarketScan, information on 
insurance type and region where the patient resides. We defined comorbidities using ICD-9/10 
diagnosis codes in the outpatient or inpatient seting prior to the index HF date (Supplementary 
Table  S1B).  To improve the sensitivity and  positive  predictive  value  of  hyperlipidemia and 
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diabetes  melitus,  we  used diagnosis codes  or the  prior  use  of a statin  or  diabetes  medication, 
respectively. Similarly, we defined coronary and peripheral artery disease using diagnosis codes 
or through relevant procedure codes such as coronary artery bypass grafting, or vascular shunt or 
bypass.  We  defined time-fixed  baseline  medication  use as a  dispensing  or  prescribing that 
overlapped the index HF date, or within 6 months prior to the index HF date. Diuretic class and 
ACEi/ARB use were modeled as baseline (time-fixed) and time-varying use, alowing for a 60-
day gap in prescriptions. We also calculated patients’ Charlson Comorbidity Index (CCI) score. 
(90, 91) 
 
3.3.6 Statistical analysis 
We calculated frequencies,  means, and  proportions  of cohort characteristics, including 
demographics, comorbidities, and prior medication use. We computed cumulative incidence of 
spironolactone initiation  over three  years after incident  HF; in  Geisinger,  we incorporated the 
competing event  of  death.  Competing risk analyses  were  not  performed in  MarketScan as 
mortality were not available. 
 
We used Cox proportional hazards regression models with robust variance estimators to quantify 
the association  between  kidney function and spironolactone initiation.   We included eGFR 
category, serum K category, diuretic class use, and ACEi/ARB use as both baseline (time-fixed), 
and time-varying exposures, in separate models. Final models were adjusted for age, sex, CCI, 
year  of  HF  diagnosis,  history  of liver  disease,  peptic  ulcer  disease, chronic  obstructive 
pulmonary  disease (COPD),  myocardial infarction,  hyperlipidemia,  hypertension, coronary 
artery disease (CAD), peripheral artery disease (PAD), cerebrovascular disease/stroke, diabetes 
melitus, cancer, cirhosis, ascites, acute  kidney injury (AKI), atrial fibrilation,  proteinuria, 
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eGFR, serum  potassium, and  prior  use  of anticoagulants,  ACE,  ARB, antiarhythmics, cardiac 
glycosides, beta-blockers, calcium channel blockers, statins, vasodilators, loop diuretics, thiazide 
diuretics, and potassium-sparing diuretics (excluding spironolactone). MarketScan analyses were 
additionaly adjusted for region of residence, and Geisinger analyses were additionaly adjusted 
for race. We combined hazard ratios (HRs) using random efects meta-analysis.  We estimated 
duration of spironolactone use after initiation using Kaplan-Meier functions, stratified by eGFR 
category, and assessed the role  of time-varying eGFR and  K in spironolactone  discontinuation 
using fuly-adjusted Cox proportional hazards regression models. 
 
Al analyses  were conducted  using  Stata 15.1 (StataCorp;  Colege  Station,  TX) and  SAS  9.4 
(SAS Institute Inc; Cary, North Carolina). 
 
3.3.7 Sensitivity analysis 
We conducted several sensitivity analyses to assess the robustness  of  our findings in  both the 
MarketScan and Geisinger cohorts. In separate analyses, we restricted the cohorts to those with 
at least two  outpatient  SCr  measurements in the  years  before their  HF  diagnosis, and to those 
with incident HF diagnosis codes referencing systolic failure (ICD-9: 428.2x & 428.4x; ICD-10: 
I50.2x & I50.4x) where it is most often used. In the Geisinger cohort, in separate analyses, we 
adjusted for time-varying systolic blood pressure (SBP), imputing SBP using multiple imputation 




3.4.1 Study population 
The MarketScan incident HF cohort (N=22,956), was 47.2% female, and had a mean age of 54.3 
years (+8.7), whereas in the Geisinger cohort (N=16,547) 51.7% were female, and the mean age 
was 74.1 years (+12.9) (Table 1B). 
 
Overal, mean eGFR was higher in MarketScan (79.2 [+21.5] mL/min/1.73m2) than in Geisinger 
(62.4 [+24.3]  mL/min/1.73m2),  with  only  17%  below  <60  mL/min/1.73m2 in  MarketScan 
compared  with  47% in  Geisinger.   Past  history  of  COPD,  hyperlipidemia,  hypertension,  CAD, 
and diabetes were common (>30%) in both cohorts.  Previous use of ACEi, beta-blockers, and 
statins were also common (>40% with previous use). The proportion of patients with previous 
use of loop (N=8,185, 35.7%) and thiazide (N=3,429, 14.9%) diuretics at baseline was lower in 
the  MarketScan cohort compared to  Geisinger (N=12,468 [75.3%] and N=5,372 [32.5%], 
respectively). 
 
3.4.2 Spironolactone initiation 
Among the  22,956  patients in  MarketScan and  16,547 in  Geisinger,  median folow-up after 
incident  HF  date  was  13.3  months (interquartile range [IQR]:  19.9  months) and  22.0  months 
(IQR:  46.1  months), respectively.  Overal,  1,398  of the incident  HF  patients in  MarketScan 
initiated spironolactone (3.5 per 1,000 person-months), and 1,747 of the incident HF patients in 
Geisinger (3.1  per  1,000  person-months).  Rates  of spironolactone initiation  were lower  with 
lower eGFR (3.4,  3.1,  3.0,  2.0  per  1,000  person-months for  ≥90,  89-60,  59-30,  <30 
mL/min/1.73m2, respectively) in Geisinger; however, in MarketScan, this was not observed (3.2, 
3.4, 5.1, 3.2 per 1,000 person-months for ≥90, 89-60, 59-30, <30 mL/min/1.73m2, respectively). 
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In MarketScan (Figure 1B), cumulative incidence of spironolactone initiation was 5.6%, 7.0%, 
and 8.5% at 12, 24, and 36 months post-HF diagnosis (log rank p<0.001), respectively, whereas 
in Geisinger, cumulative incidence of spironolactone initiation was 7.9%, 9.9%, and 12.1% at 12, 
24, and 36 months post-HF diagnosis (log rank p<0.001), respectively. 
 
Median  dose at spironolactone initiation  was  25  miligrams, and this  was consistent in  both 
cohorts, across al eGFR categories. 
 
3.4.3 Kidney function as a predictor of spironolactone use 
In adjusted analyses modeling kidney function as a time-fixed variable (Table 2B), eGFR <30 
mL/min/1.73m2 was associated with a 41% lower likelihood of spironolactone initiation (HRmeta: 
0.59;  95% confidence interval [CI]:  0.47 to  0.76) compared to an eGFR  of  60-89 
mL/min/1.73m2; there was no diference in the likelihood of initiation for eGFR categories >90 
or 30-59 mL/min/1.73m2 compared to 60-89 mL/min/1.73m2. 
 
In adjusted analyses  modeling  kidney function as a time-varying exposure (Table  3B), eGFR 
<30 mL/min/1.73m2 remained associated with a decreased likelihood of initiation (HRmeta: 0.61; 
95%  CI:  0.44 to  0.83) compared to eGFR  of  60-89  mL/min/1.73m2; again, there  was  no 
diference in the likelihood  of initiation for eGFR categories >90  or  30-59  mL/min/1.73m2 
compared to 60-89 mL/min/1.73m2. 
 
Meta-analyzed results  were consistent in sensitivity analyses (Supplementary  Table  S3B) 
restricting to  only those  with routine labs  prior to  HF  diagnosis, restricting to  only those  with 
systolic  HF codes, and  when the initiation  of single-ingredient spironolactone  was  used as the 
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outcome (data  not shown).  In sensitivity analyses conducted in  Geisinger alone, results  were 
also consistent when accounting for time-varying systolic blood pressure, and the competing risk 
of death. 
 
3.4.4 Time-varying serum K and medications as predictors of spironolactone use 
Serum potassium <3.5 mEq/L was associated with an increased likelihood of initiation compared 
to 3.5-4.9 mEq/L (HRmeta: 2.40; 95% CI: 1.95 to 2.96). Loop and thiazide use were associated 
with an increased likelihood  of initiation, as  wel ([HRmeta:  2.49;  95%  CI:  2.21 to  2.80] and 
[HRmeta:  1.27;  95%  CI:  1.03 to  1.57], respectively].   Time-varying  ACEi/ARB  use  was  not 
associated with spironolactone initiation. 
 
3.4.5 Comorbidities and previous medication use 
In adjusted analyses, women were less likely to initiate spironolactone compared with men. Past 
history of cirhosis and ascites, as wel as prior use of cardiac glycosides and beta-blockers, were 
strongly associated with spironolactone initiation, and a history of acute kidney injury (AKI) and 
atrial fibrilation were associated with lower likelihood of spironolactone initiation. 
 
3.4.6 Duration and discontinuation of spironolactone use 
Median duration of spironolactone use was 6.3 and 10.2 months in MarketScan and Geisinger, 
respectively. Duration was shorter with lower eGFR in both cohorts (Figure 2B). 
 
Among spironolactone initiators,  855 and  1,447  patients  discontinued spironolactone after 
initiation in MarketScan and Geisinger, respectively. In the 30 days prior to discontinuation, 107 
patients had at least one hospitalization (13% of individuals discontinuing spironolactone), and 
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18 had two or more in the MarketScan cohort; AKI was noted as the cause for hospitalization in 
nine patients. Of the 1,447 patients at Geisinger who discontinued spironolactone, 424 patients 
(29% of individuals discontinuing spironolactone) had at least one hospitalization in the 30 days 
prior to their  discontinuation, and  62  had two  or  more;  AKI  was  noted in  49  patients and 
hyperkalemia was noted in five patients as the cause for hospitalization.  
 
For time-to-event analyses using time-varying lab data, serum K >5.0 mEq/L was a risk factor 
for discontinuation in both cohorts, compared with 3.5-4.9 mEq/L; in Geisinger, serum K <3.5 
mEq/L  was also a risk factor for  discontinuation, as  wel as eGFR  <30  mL/min/1.73m2 
(compared with >90 mL/min/1.73m2). 
 
3.5 Discussion 
In this analysis  of two large cohorts  of  patients  with  HF,  one derived from commercial claims 
(MarketScan) and one derived from EHR data (Geisinger), use of spironolactone was low, with 
fewer than one in ten individuals initiating use within two years of a new diagnosis of HF. After 
controling for concurent comorbidities and  medication  use, those  with the lowest level  of 
kidney function were the least likely to initiate spironolactone. Among initiators, the duration of 
use  was short, especialy among those  with lower  kidney function.  Our findings are important 
because  data  on the  use  of spironolactone in  U.S.  patients  with  HF are limited, and they  have 
potential implications for both prescribers and regulators as spironolactone is being evaluated for 
use in patients with less severe HF, and across the spectrum of kidney function.(101)  
 
Immediately after the  Randomized  Aldactone  Evaluation  Study (RALES)(41) demonstrated 
spironolactone’s efectiveness in reducing cardiovascular  hospitalization and  death in  patients 
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with HFrEF in 1999, utilization of spironolactone increased by a factor of up to five in several 
health systems around the world;(104, 105)  however, whether this efect has persisted has not 
been assessed. We found that, overal, spironolactone use is modest in the seting of HF in two 
U.S.-based cohorts, even lower than  what  has  been  observed from cohorts  outside  of the  U.S. 
where  prevalence  of use ranged from roughly  15% to  30%. (106-109)  Our results support an 
analysis by Dev et al (102) which found that aldosterone antagonists may be underutilized as a 
class in the  U.S., even among ideal candidates.  Dev et al speculate the  underutilization is 
primarily  due to  provider-based  bariers, specificaly lack  of coordination  of care  between 
providers and experience with prescribing aldosterone antagonists. Some other possible bariers 
that  may account for the low rates  of  use include concern regarding  potential adverse efect 
profile, limited  pharmaceutical  marketing and  promotion, regulatory advisories  or label 
warnings, and coverage and reimbursement policies. 
 
While spironolactone is not explicitly contraindicated in those with lower eGFR in its Food and 
Drug  Administration (FDA)  drug label,(19) the  AHA  guidelines for  HFrEF recommend 
aldosterone antagonists in patients with eGFR >30 mL/min/1.73 m2 (SCr of <2.5 mg/dL in men 
or <2.0 mg/dL in women), and potassium <5.0 mEq/L.(99, 100) Similarly, the Kidney Disease: 
Improving  Global  Outcomes (KDIGO) guideline  on the treatment  of  hypertension in  CKD 
supports the  use  of  diuretics in  patients  with  CKD, but recommends caution  with  prescribing 
spironolactone and  other aldosterone antagonists.(12) We found that spironolactone initiation 
among those with eGFR <30 ml/min/1.73 m2 was consistently low. Across both cohorts, those 
with eGFR <30 mL/min/1.73m2 were the least likely to initiate spironolactone, and among those 
who were prescribed the drug, they also had the shortest duration of use. These findings suggest 
that  kidney function remains an important clinical factor in  whether  patients are  prescribed 
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spironolactone, and that  providers  may  believe the risks  of  hyperkalemia  outweigh 
spironolactone’s benefits in some higher risk patients.  
 
Patients with serum creatinine >2.5 mg/dL were excluded from RALES. As such, efectiveness 
was  never established in the seting  of reduced  GFR in that  original study.  However, since its 
publication, clinical trial data suggest that  patients  with lower  GFR  would  benefit from 
spironolactone’s cardiovascular efects.(26,  38-40) Additionaly, spironolactone and  other 
aldosterone antagonists  with antifibrotic/antiproteinuric  properties  may also confer renal 
benefit.(30, 31, 33, 110) As a pleiotropic hormone, spironolactone may be particularly promising 
in  patients  with  CKD  where there are limited therapeutic  options, and  where refractory 
hypertension is common.(111)  More  data are  needed  on  how the  benefit-to-risk ratio  of these 
drugs varies across the spectrum kidney function. 
 
Our study  has a few  notable strengths.  We  used two large electronic  data resources  with 
longitudinal records over extended time periods, including recent years where published data on 
spironolactone use is particularly limited. Data included laboratory measures of serum creatinine 
and  potassium, and in  Geisinger, clinical  measurement  of  blood  pressure. There are some 
limitations that  must also  be  noted.   Data  used in this study  were  not colected for research 
purposes.  We  used  diagnosis codes to  define comorbidities, and some  may  have limited 
sensitivity and specificity. While we did conduct a sensitivity analyses looking at only systolic 
failure, we could not diferentiate diferent types of HF using ICD-9/10 diagnosis codes for most 
patients.  Medication  data  were  obtained through  prescription claims (MarketScan) and  orders 
(Geisinger), and adherence could  not  be  verified.  Finaly, compared  with the  Geisinger  data, 
folow-up in  MarketScan  was somewhat limited, and  we  did  not  observe clear  diferentiation 
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between eGFR categories when calculating estimates of cumulative incidence of spironolactone 
initiation; this may be a function of unreported lab results for MarketScan cohort members. 
 
3.6 Conclusions 
We found that spironolactone initiation was uncommon among patients with incident HF in two, 
large  U.S.-based cohorts.  Spironolactone initiation  was least likely in those  with eGFR  <30 
mL/min/1.73m2, after accounting for concurent comorbidities and medication use. Duration of 
use after initiation  was also shortest among those  with the lowest levels  of  kidney function. 
Overal, these findings suggest that spironolactone is  prescribed fairly infrequently to  patients 
with  heart failure,  particularly among  patients  with low eGFR.  Further research is  needed to 
beter establish a  benefit-to-risk  profile for spironolactone among  patients  with  HF across the 
spectrum  of  kidney function, and whether it  may  be co-prescribed  with  potassium  binders to 













Table 1B: Sample characteristics, by cohort 
 
Table 1B Key:  
Angiotensin-converting enzyme 
inhibitors (ACEi); Angiotensin I 
receptor blockers (ARB); 
cerebrovascular disease (CEVD); 
Charlson Comorbidity Index (CCI); 
chronic obstructive pulmonary disease 
(COPD); estimated glomerular filtration 
rate (eGFR); standard deviation (SD); 
serum creatinine (SCr); serum 
potassium (K). 
 
Count (percentage) are presented for 


















N (Total) 22,956 16,547
Female 10,830 (47.2%) 8,560 (51.7%)
Age (mean and SD) 54.3 (8.7) 74.1 (12.9)
Race (non-white) n/a 341 (2.1%)
Kidney function, SCr, and K levels
  serum creatinine (mean and SD) 1.0 (0.5) 1.2 (0.6)
  eGFR (mean and SD) 79.2 (21.5) 62.4 (24.3)
  eGFR (category)
    >90 mL/min/1.73m2 8,590 (37.4%) 2,379 (14.4%)
    60-89 mL/min/1.73m2 10,541 (45.9%) 6,467 (39.1%)
    30-59 mL/min/1.73m2 3,125 (13.6%) 6,218 (37.6%)
    <30 mL/min/1.73m2 700 (3.1%) 1,483 (9.0%)
  serum potassium (mean and SD) 4.3 (0.5) 4.3 (0.5)
  serum potassium (category)
    <3.5 mEq/L 588 (2.6%) 623 (3.8%)
    3.5-4.9 mEq/L 20,555 (89.6%) 14,170 (85.6%)
    >5.3 mEq/L 1,809 (7.9%) 1,754 (10.6%)
CCI (mean and SD) 4.5 (2.6) 7.0 (2.8)
Comorbidities
  liver disease 2,894 (12.6%) 1,041 (6.3%)
  peptic ulcer disease 609 (2.7%) 924 (5.6%)
  COPD 7,613 (33.2%) 7,946 (48.0%)
  myocardial infarction 3,206 (14.0%) 3,415 (20.6%)
  hyperlipidemia 15,757 (68.6%) 12,736 (77.0%)
  hypertension 18,946 (82.5%) 13,980 (84.5%)
  coronary artery disease 9,158 (39.9%) 8,591 (51.9%)
  CEVD/stroke 3,994 (17.4%) 4,558 (27.5%)
  peripheral artery diseaee 3,083 (13.4%) 3,392 (20.5%)
  diabetes 10,078 (43.9%) 7,289 (44.1%)
  cancer 3,013 (13.1%) 3,357 (20.3%)
  cirhosis 369 (1.6%) 180 (1.1%)
  ascites 646 (2.8%) 218 (1.3%)
  acute kidney injury 2,360 (10.3%) 2,830 (17.1%)
  atrial fibrilation 3,339 (14.5%) 5,716 (34.5%)
  proteinuria 1,116 (4.9%) 974 (5.9%)
Previous medication use
  anticoagulants 5,127 (22.3%) 8,709 (52.7%)
  ACEi 9,199 (40.1%) 9,239 (55.8%)
  ARB 4,993 (21.8%) 2,973 (18.0%)
  antiarythmic 2,440 (10.6%) 2,940 (17.8%)
  cardiac glycoside 1,280 (5.6%) 2,359 (14.3%)
  beta blocker 12,980 (56.5%) 12,736 (77.0%)
  calcium channel blocker 6,934 (30.2%) 6,397 (38.7%)
  statin 10,402 (45.3%) 10,196 (61.6%)
  vasodilator 1,837 (8.0%) 1,311 (7.9%)
Previous diuretic use
  loop diuretic 8,185 (35.7%) 12,468 (75.3%)
  thiazide diuretic 3,429 (14.9%) 5,372 (32.5%)
  K-sparing diuretic 946 (4.1%) 598 (3.6%)
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Table 2B: Time-fixed predictors of spironolactone initiation, by cohort and meta-analyzed 
 
Table 2B Key: * p<0.05; angiotensin-converting enzyme inhibitors (ACE); angiotensin I receptor blockers (ARB); 
cerebrovascular  disease (CEVD); chronic  obstructive  pulmonary  disease (COPD); confidence interval (CI); 
estimated  glomerular filtration rate (eGFR);  hazard ratio (HR);  heart failure (HF);  northcentral (NC);  northeast 
(NE); not applicable (n/a); potassium (K); reference (ref); serum creatinine (SCr); south (S); west (W) 
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rate (eGFR); hazard 
ratio (HR); heart failure 
(HF); northcentral 
(NC); northeast (NE); 
not applicable (n/a); 
potassium (K); 
reference (ref); serum 
creatinine (SCr); south 
(S); west (W); 
 
This model included 
both time-fixed and 
time-varying covariates 
(as noted). ACEi and 













Supplementary Table S1B: Operationalized definitions for patient comorbidities 
 
Supplementary  Table  S1B Key:  Diabetes  drugs include,  but are  not limited to, insulin,  biguanides, sulfonylureas, 
alpha-glucosidase inhibitors, and thiazolidinediones. cerebrovascular  disease (CEVD); International  Classification 









Supplementary Table S2B: Incident heart failure codes, by cohort 
 
Supplementary Table S2B Key: * = the vast majority were for code 402.x 
 
 




Supplementary  Table  S3B Key:  *  =  p<0.05; Angiotensin-converting enzyme inhibitors (ACEi); angiotensin I 
receptor blockers (ARB); confidence interval (CI); estimated glomerular filtration rate (eGFR); heart failure (HF); 
hazard ratio (HR); not applicable (n/a); reference (ref); Al sensitivity models used were fuly-adjusted and included 
time-varying eGFR, K, diuretic class use, and ACEi/ARB. Sensitivity 1 analyses were restricted to patients with at 
least two lab measurements any year before HF diagnosis (MarketScan N=15,385; Geisinger N=15,504). Sensitivity 
2 analyses  were restricted to  patients  with incident systolic  or combined systolic  +  diastolic  HF (MarketScan 
N=2,355;  Geisinger  N=2,573). Sensitivity  3 analyses included time-varying systolic  blood  pressure (Geisinger 
N=16,547). Sensitivity 4 analyses used a competing risk (death) framework (Geisinger N=16,547). 
MarketScan Geisinger
N (Total number of patients) 22,956 16,547
Heart failure, unspecified (428.0, I50.9) 15,258 (66%) 10,541 (64%)
Systolic code (428.1x, I50.2x) 1,887 (8%) 2,382 (14%)
Diastolic code (428.3x, I50.3x) 2,647 (12%) 2,569 (16%)
Combined systolic and diastolic code (428.4x, I50.4x) 468 (2%) 191 (1%)
Al other codes* 2,696 (12%) 864 (5%)
Sensitivity 1: HR (CI)Sensitivity 2: HR (CI)Sensitivity 3: HR (CI)Sensitivity 4: HR (CI)
MarketScan eGFR category 
>90 mL/min/1.73m
2 0.89 (0.77-1.03) 0.71 (0.53-0.95)* n/a n/a
60-89 mL/min/1.73m
2 ref ref n/a n/a
30-59 mL/min/1.73m
2 0.97 (0.81-1.16) 0.84 (0.58-1.22) n/a n/a
<30 mL/min/1.73m
2
0.50 (0.33-0.72)* 0.52 (0.23-1.19) n/a n/a
Geisinger eGFR category 
>90 mL/min/1.73m2 0.90 (0.76-1.06) 1.01 (0.72-1.41) 0.95 (0.80-1.09) 0.90 (0.77-1.05)
60-89 mL/min/1.73m
2 ref ref ref ref
30-59 mL/min/1.73m
2 1.04 (0.93-1.18) 0.94 (0.72-1.24) 1.04 (0.93-1.17) 1.04 (0.93-1.17)
<30 mL/min/1.73m2 0.69 (0.54-0.88)* 0.44 (0.22-0.85)* 0.68 (0.54-0.86)* 0.59 (0.47-0.75)*
Meta-analyzed: HRmeta (CI)
>90 mL/min/1.73m2 0.89 (0.80-1.00) 0.84 (0.59-1.18) n/a n/a
60-89 mL/min/1.73m2 ref ref n/a n/a
30-59 mL/min/1.73m2 1.02 (0.92-1.12) 0.90 (0.73-1.13) n/a n/a











Supplementary Figure S1B Key: end-stage renal disease (ESRD); heart failure (HF); serum creatinine (SCr); serum 
potassium (K); United States Renal Data System (USRDS). We defined “baseline lab window” as 180 days before 
through seven days after index HF diagnosis. For both MarketScan and Geisinger, we defined patients’ HF index 
date as the first HF diagnosis code date; to ensure this was an incident diagnosis, patients were required to have had 
at least 90 days of available claims (MarketScan) or records in the EHR (Geisinger) to check for prior HF codes. If 



















Patients with HF and labs
At least 18 years old
Without prior spironolactone use
Without prior ESRD diagnosis or 
USRDS registry
At least 90 days of lookback in 
the data
Available SCrand K lab captured 
in “baseline lab window”
67,369 32,556
N = 22,956 N = 16,547
n= 500 from MarketScan






















Supplementary Figure S2B Key: Heart failure (HF); serum creatinine (SCr); serum potassium (K); To be included, patients must have had at least 90 days of 
available claims  or records  with  no  HF code  noted  or spironolactone  prescription, and available  SCr and  K labs in the “baseline lab  window”.  Patients  were 
censored at incident spironolactone  use  or last record in the  data,  whichever came first.  Geisinger analysis included competing risk  of  death as sensitivity 
analysis.
Incident spironolactone use 
or censoring 7 days
Index HF 
diagnosis
“Baseline lab window”: closest SCrand K to 
index HF diagnosis selected as baseline measure
180 days
Folow-up time
No HF code or spironolactone use 
(must be at least 90 days)
First record in data
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4 Hyperkalemia and acute  kidney injury  with spironolactone  use 
among patients with heart failure 
 
4.1 Abstract 
Background: The risk of hyperkalemia and acute kidney injury (AKI) with spironolactone use 
among  patients  with  heart failure is  unclear,  particularly in  patients  with reduced  kidney 
function. 
Methods: We identified  17,110  patients  with  heart failure treated  with loop  diuretics  between 
2004 and 2016 within the Geisinger Health System. We estimated the incidence of hyperkalemia 
and AKI associated with the addition of spironolactone and used target trial emulation methods 
to  minimize confounding  by indication.  We report risks associated  with the addition  of 
spironolactone compared to loop diuretics alone by level of kidney function. 
Results: Over a  mean folow-up  of  134  months,  18.9% (N=3,229) initiated spironolactone. 
Patients initiating spironolactone  were  younger and  had a  higher  mean estimated  glomerular 
filtration rate (eGFR) (p=0.001 for  both). In as-treated analyses, incidence rates (IRs)  of 
hyperkalemia were highest when patients were on spironolactone without a loop diuretic (3.3 per 
1,000  person-months), folowed  by  both loop  diuretics and spironolactone (2.9), loop  diuretics 
alone (1.4), and  neither (1.3).  The IRs for  AKI  were  highest  when  patients  were  on  both loop 
diuretics and spironolactone (10.1), folowed by loop alone (7.4), spironolactone alone (5.3), and 
neither (4.6). In  propensity score  matched target trial emulation, spironolactone initiation  was 
associated  with a  moderate increase in  hyperkalemia risk and a smal increase in  AKI risk 
compared to loop alone [hazard ratio (HR)  1.69 (confidence interval (CI):  1.35-2.10), and  HR 
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1.12 (CI:  1.00-1.26), respectively].  There  were  no  diferences in the relative risk  of either 
outcome associated with spironolactone by level of eGFR (al interactions p>0.05). 
Conclusion: The addition  of spironolactone to loop  diuretics in  patients  with  heart failure 
increases the risk  of  hyperkalemia, and to a lesser  degree,  AKI.  While the absolute risks  were 
higher for  both  outcomes among those using spironolactone with reduced  kidney, the relative 
risks associated with spironolactone were not diferent by level of kidney function. These risks 
must be weighed against the potential benefits of spironolactone. 
 
4.2 Introduction 
Spironolactone is an aldosterone antagonist indicated for the treatment  of  New  York  Heart 
Association  Class II-IV  heart failure  with reduced ejection (HFrEF).(19) Concomitant 
spironolactone and loop  diuretics  decreased  heart failure  hospitalization and  mortality among 
patients  with  HFrEF in the landmark  Randomized  Aldactone  Evaluation  Study (RALES) 
study.(41)  Evidence for spironolactone’s efectiveness among  patients  with  heart failure  with 
preserved ejection (HFpEF) is less established,(112) but data from the Treatment of Preserved 
Cardiac  Function  Heart  Failure  with an  Aldosterone  Antagonist (TOPCAT) trial suggest a 
benefit for spironolactone in HFpEF, with a protective efect for heart failure hospitalization but 
not mortality.(113) Nevertheless, any benefits associated with spironolactone must be weighed 
in the context  of its  known serious risks, specificaly  hyperkalemia and acute  kidney injury 
(AKI).(19, 32, 43, 104, 114-119) 
 
Most  prior clinical trials  of spironolactone focused  on  patient  populations  with relatively 
preserved  kidney function. In  both  RALES and  TOPCAT,  patients  with estimated  glomerular 
filtration rate (eGFR)  <30  mL/min/1.73m2, serum creatinine (SCr)  >2.5  mg/dL, and serum 
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potassium (K)  >5.0  mEq/L  were excluded.(41,  113)  In addition,  patients’  SCr and  K  were 
regularly monitored during study visits, alowing for dose adjustments and discontinuation that 
may  have  mitigated the risk  of  hyperkalemia and  AKI. The risks  of spironolactone in less 
controled, real-world setings are  not  wel  understood,  particularly among those  with reduced 
kidney function who are already at higher risk for hyperkalemia and AKI.  
 
Despite curent clinical guidelines recommending aldosterone antagonists use only at eGFR >30 
mL/min/1.73m2,(99, 100) patients are prescribed spironolactone across al levels of eGFR.(44) 
Randomized controled trials are  ongoing to  beter  understand  whether aldosterone antagonists 
provide cardiovascular and renal  benefit in  patients  with advanced chronic  kidney  disease 
(CKD).(101) Given the existing use, and potential for expanded use in patients with HFpEF and 
lower kidney function, there are important unanswered questions regarding the real-world safety 
profile  of spironolactone in the context  of concurent comorbidities and  medications. Because 
previous work suggests that spironolactone is most commonly used in addition to loop diuretics, 
and  because the later  may also  modify the risks  of  hyperkalemia and  AKI,  we  quantified the 
absolute and relative risks of hyperkalemia and AKI associated with spironolactone use among a 
population of patients with heart failure on loop diuretics, and evaluated for diferential risk by 
level of kidney function. 
 
4.3 Methods 
4.3.1 Data source and population 
We  used integrated electronic  health record (EHR)  data from the Geisinger  Health  System 
(Geisinger) in  Pennsylvania,  United  States. These  EHR  data include inpatient and  outpatient 
records for  patients receiving their  primary care at  Geisinger, as  wel as  medication  orders, 
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medication reconciliation and laboratory results. We included patients age 18 years or older with 
a  heart failure  diagnosis code from inpatient  or  outpatient records and a subsequent  outpatient 
prescription for a loop  diuretic from  2004-2016 (Supplementary Table  S1C). We excluded 
patients  with end-stage renal  disease (ESRD), those  with spironolactone  use  prior to the first 
loop diuretic order in the data, and patients without an antecedent serum creatinine or potassium. 
 
4.3.2 Study designs and exposure definitions 
To determine the incidence of hyperkalemia and AKI during real-world use of spironolactone in 
heart failure, we performed an as-treated analysis, with patients’ time at risk (T0) starting at the 
first loop diuretic prescription after their initial heart failure diagnosis. We classified time at risk 
according to time-varying loop  diuretic and spironolactone  use (single-ingredient [SI] 
spironolactone  or combination spironolactone  with  hydrochlorothiazide). In the continuous  use 
periods,  we alowed for a  30-day  gap  between the end  of  one  prescription and the start  of the 
next for the same medication, and included a 15-day “washout” period at the end of a continuous 
use episode  where  outcomes could stil  be  observed.  Primary exposure  groups in the time-
varying, as-treated analysis  were thus loop  diuretic  use  without spironolactone (loop alone), 
spironolactone use without a loop diuretic (spironolactone alone), concomitant use of both a loop 
diuretic and spironolactone, and no use of either drug. 
 
To strengthen evidence for a causal relationship between spironolactone and hyperkalemia and 
AKI,  we  performed a target trial emulation  with an intention-to-treat (ITT)  design.(120-123) 
This  method,  particularly  when combined  with  propensity score  matching,  helps to minimize 
confounding  by indication, alowing for a  direct assessment  of the risks associated  with 
spironolactone in comparable  patients.  We  utilized the ITT  principle (i.e. treatment 
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assignment/status at baseline is caried forward regardless of subsequent changes to treatment) to 
analyze a series of “trials” where each “trial” represents a fixed time window when a patient may 
or may not begin a specific treatment regimen. To mimic a hypothetical “trial” selection process, 
enrolment criteria in each “trial” (cohort  years: [1]  2004-2006, [2]  2007-2009, [3]  2010-2012 
and [4]  2013-2016) included  heart failure  diagnosis, loop  diuretic  prescription  order,  no  prior 
spironolactone order, and potassium <5.0 mEq/L. Within each “trial”, patients who received an 
initial spironolactone prescription were compared to eligible patients who did not. Time at risk 
(T0) began  on the  date  of the first spironolactone  prescription for spironolactone  users 
(treatment), and a random loop  prescription  during that “trial”  period for controls.  Control 
patients were eligible to be treatment or control patients in subsequent “trials”, whereas treatment 
patients were no longer eligible due to their previous spironolactone use. In the final analysis, the 
“trial” cohorts were pooled to create a combined dataset. 
 
4.3.3 Study outcomes 
In  both the as-treated and ITT analyses,  patients  were folowed  until the  outcomes  of interest 
(hyperkalemia and  AKI),  death, last recorded  health care encounter  date (including inpatient, 
outpatient, laboratory, or medication order dates), or the end of the study period (December 31st, 
2016), whichever came first. We defined hyperkalemia by inpatient International Classification 
of Disease, Ninth Revision (ICD-9) or ICD-10 codes 276.7 or E87.5, respectively, and AKI by 
inpatient ICD-9 or ICD-10 codes 584.9 or N17.9, respectively. 
 
4.3.4 Kidney function, potassium, and other covariates 
We defined eGFR based on outpatient serum creatinine (SCr) and the Chronic Kidney Disease 
Epidemiology Colaboration (CKD-EPI) equation.(88) We classified eGFR using four primary 
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categories (≥90  mL/min/1.73m2; 60-89 mL/min/1.73m2; 30-59 mL/min/1.73m2;  <30 
mL/min/1.73m2), and as linear splines  with a  knot at  60  mL/min/1.73m2.  We classified serum 
potassium (K) levels using three categories (<3.5 mEq/L; 3.5-4.9 mEq/L; >5.0 mEq/L), and as 
linear splines with knots at 3.5 mEq/L and 4.9 mEq/L; in the ITT analysis, only one knot was 
used (3.5  mEq/L). Baseline  SCr and  K  were considered the closest  measurements to  T0 within 
the window of 365 days before to seven days after that date. If there was no available outpatient 
SCr or K, we used available inpatient SCr or K within the same window. 
 
Other medications were captured as prescriptions that overlapped T0 and were modeled as time-
fixed  variables; the exception  was angiotensin-converting-enzyme inhibitor (ACEi)  or 
angiotensin I receptor blockers (ARB) use, which was modeled as a time-varying variable in the 
as-treated analysis.   We  defined comorbidities  using ICD-9/10  diagnosis codes in the  EHR 
(Supplementary Table S1C). We also calculated patients’ Charlson Comorbidity Index (CCI) 
score.(90, 91) 
 
4.3.5 Statistical analysis 
We calculated frequencies,  means, and  proportions  of the  primary analytic cohorts’ 
characteristics at T0, including demographics, comorbidities, and prior medication use. We also 
stratified cohort characteristics  by ever/never spironolactone initiators (in as-treated analyses), 
and cohort “trial”  years (in ITT analyses), and we assessed for trends  using logistic and linear 
regression for  binary and continuous  variables, respectively.  We calculated incidence rates for 
hyperkalemia and  AKI (per  1,000  person-months)  by as-treated exposure  groups,  both  overal 
and stratified  by time-varying eGFR category.  We also calculated and  ploted cumulative 
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incidence of hyperkalemia and AKI over three years after T0 in the ITT analyses, incorporating 
the competing event of death, and stratifying by eGFR. 
 
We  used time-to-event  Fine and  Gray regression  models to estimate subdistributional  hazards 
ratios (sHR) accounting for the competing risk  of  death.(124)  We choose the  Fine and  Gray 
method because it does not assume the competing event (death) is non-informative, and censored 
as such.  With respect to the  outcomes  of interest,  hyperkalemia and  AKI, this assumption is 
likely not appropriate.  Comparing exposure groups in as-treated analyses, we used unadjusted 
and fuly-adjusted models with time-fixed covariates, as wel as adjusted models where eGFR, 
K, and  ACEi/ARB  use  were included as time-varying covariates. In as-treated analyses,  we 
tested for an interaction between time-varying eGFR (linear spline) and exposure group. In ITT 
analyses comparing treatment to control groups, we used unadjusted and fuly-adjusted models, 
as  wel as adjusted  models  weighted  by the inverse  probability  of treatment (IPTW), and  1:1, 
“nearest-neighbor”  propensity score (PS)  matched analyses  using calipers of 0.014; after 
matching, al standardized mean diferences were <0.10. In the ITT analyses, we also tested for 
an interaction  between  T0 eGFR (linear spline) and treatment.  We  used robust  variance 
estimators to account for within-person corelation. To assess for a heterogeneity of efect among 
cohort “trial”  years in the ITT analyses,  we tested for an interaction  between “trial” and 
treatment status, and found no statisticaly significant interaction. 
 
We adjusted final models for age, sex, race (non-white), eGFR (linear spline), K (linear spline), 
time  with  heart failure,  year  of first loop  order,  CCI,  history  of  hyperkalemia, history  of AKI, 
cardiovascular  disease (CVD),  peripheral artery  disease (PAD),  diabetes  melitus, cancer, 
cirhosis, ascites, atrial fibrilation,  proteinuria, and  prior  use  of anticoagulants,  ACEi,  ARB, 
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other antihypertensives (combined:  beta-blocker, calcium channel  blockers,  vasodilators), 
antiarhythmics, cardiac  glycosides, statins, thiazide  diuretics, and  potassium-sparing  diuretics 
(excluding spironolactone). ITT analyses  were additionaly adjusted  by time  between the first 
loop  order and  T0. We  used the same covariates to calculate the  propensity scores, and  we 
calculated stabilized weights for IPTW analyses. 
 
Al analyses  were conducted  using  Stata  15.1 (StataCorp;  Colege  Station,  TX) and  SAS  9.4 
(SAS Institute Inc; Cary, North Carolina). 
 
4.4 Results 
4.4.1 Study population 
There were 17,110 patients with heart failure who used loop diuretics during the study period; 
50.5% were female (N=8,635), 2.4% were non-white (N=414), and the mean (standard deviation 
[SD]) age  was  73.2 (13.0) years (Table  1C).  Diabetes (46.6%;  N=7,977) and  CVD (66.3%; 
N=11,347)  were common, as  was the  use  of  ACEi/ARB (80.2%;  N=13,726), statins (66.2%; 
N=11,331), anticoagulants (59.8%; N=10,233), and other antihypertensives (89.5%; N=15,308). 
Roughly  19% (N=3,229)  went  on to initiate spironolactone  over a  mean folow-up  of  134 
months; these  patients  were  younger and  had  higher  mean eGFRs at  baseline compared  with 
never initiators (p=0.001 for both). 
 
4.4.2 Real-world incidence of hyperkalemia and AKI 
There  were  995  hyperkalemia events (7,287  deaths) in  681,944  person-months (PMs)  of 
observation time.  Overal, incidence rates (IRs)  per  1,000  PMs  were  highest for those  on 
spironolactone  without a loop  diuretic (3.3), folowed  by concomitant loop and spironolactone 
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(2.9), loop  without spironolactone (1.4), and  no  use  of either (1.3) (Table  2C).  In adjusted 
models  with time-varying eGFR,  K, and  ACEi/ARB  use,  both concomitant loop and 
spironolactone, and spironolactone alone, were associated with a more than two-fold increase in 
the risk  of  hyperkalemia (sHR  2.06 [Confidence Interval [CI]:  1.70-2.49] and sHR  2.28 [CI: 
1.40-3.69], respectively) compared to loop use without spironolactone (Table 3C). 
 
There were 4,212 AKI events (5,387 deaths) in 620,094 PMs of observation time. In contrast to 
trends in hyperkalemia, IRs per 1,000 PMs for AKI were highest for those on concomitant loop 
and spironolactone (10.1), folowed by loop without spironolactone (7.4), spironolactone without 
a loop (5.3), and  no  use  of either (4.6). In adjusted  models  with time-varying covariates, 
concomitant loop and spironolactone  was associated  with a  37% increase in the risk  of  AKI 
(sHR  1.37 [CI:  1.23-1.53]) compared to loop  use without spironolactone,  but there  was  no 
statisticaly significant  diference in risk  with spironolactone alone  without the  use  of a loop 
diuretic (sHR 0.77 [CI: 0.52-1.13]). 
 
Although the absolute risks of hyperkalemia and AKI increased in lower eGFR categories, there 
were  no  diferences in the relative risks  of these adverse  outcomes  by eGFR (interaction with 
exposure groups not statisticaly significant; p>0.05). 
 
4.4.3 Target trial emulation assessing add-on spironolactone therapy 
In the  pooled target trial emulation, there  were  24,127  patients [treatment  group (concomitant 
loop and spironolactone) = 2,000; control group (loop without spironolactone) = 22,127]. More 
than  half (51.8%,  N=12,499)  were female, and  mean (SD) age  was  73.8 (12.7)  years 
(Supplementary Table S2C). 
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There were 1,197 hyperkalemia events (163 in the treatment group) (Table 4C), with a one-year 
cumulative incidence  of  1.7% and  4.0% in the control and treatment  groups, respectively. 
Cumulative incidence of  hyperkalemia at  one  year  was lowest for  patients  with  T0 eGFR >60 
mL/min/1.73m2 in the control group (1.2%), folowed by those with eGFR >60 mL/min/1.73m2 
in the treatment  group and those  with eGFR  <60  mL/min/1.73m2 in the control  group (both 
2.1%); those with eGFR <60 mL/min/1.73m2 in the treatment group had the highest cumulative 
incidence (6.3%) (Figure  1C). In the fuly-adjusted  model (Figure  2C), treatment  was 
associated with an increase in the risk of hyperkalemia compared to control (sHR 1.75 [CI: 1.46-
2.09]), and this was similar when using IPTW (sHR 1.58 [CI: 1.28-1.94]) and 1:1 PS-matching 
(N=1,976 in each group; sHR 1.69 [CI: 1.35-2.10]).  
 
There were 5,582 AKI events (560 in the treatment group), with a one-year cumulative incidence 
of 9.5% and 14.9% in the control and treatment groups, respectively. Similar to hyperkalemia, 
cumulative incidence  of  AKI at  one  year  was lowest for  patients  with  T0 eGFR >60 
mL/min/1.73m2 in the control group (5.8%), folowed by those with eGFR >60 mL/min/1.73m2 
in the treatment group (10.8%), and those with eGFR <60 mL/min/1.73m2 in the control group 
(13.1%); those  with eGFR  <60  mL/min/1.73m2 in the treatment  group had the  highest 
cumulative incidence (20.2%).  In the fuly-adjusted  model, treatment  was associated  with an 
increased risk of AKI compared to control (sHR 1.18 [CI: 1.08-1.30]) and this was similar when 




Similar to the as-treated analysis, there were no diferences in the relative risks of hyperkalemia 
or AKI by eGFR (interaction with treatment status not statisticaly significant; p>0.05). 
 
4.5 Discussion 
In this large, real-world cohort  of  patients  with  heart failure  prescribed loop  diuretics, 
approximately one in five  were  prescribed spironolactone.  The cohort  was at  high risk for 
hyperkalemia and AKI, with the highest rates among patients with eGFR <60 mL/min/1.73m2, 
and those prescribed spironolactone. In a propensity-matched, target trial emulation, we observed 
a 69% increased risk of hyperkalemia with spironolactone compared to loop diuretics alone, and 
a 12% increased risk of AKI. The relative risks of hyperkalemia and AKI were not modified by 
renal function in either analyses. These findings are important because relatively litle is known 
about the real-world safety  of spironolactone,  particularly among a  broader  heart failure 
population (HFrEF and HFpEF) across the spectrum of kidney function. 
 
A  more complete  understanding  of spironolactone-associated  hyperkalemia and  AKI is critical 
for utilization to expand to higher risk patients excluded from the clinical trials. In RALES, the 
pivotal study that established spironolactone’s efectiveness in HFrEF, the cumulative incidence 
of hyperkalemia was very modest (~2% in the spironolactone group vs. ~1% in placebo among 
randomized patients over the study period),(41) likely due to the selection of a lower risk study 
population  by excluding  patients  based  on their  SCr and  K, and regular  monitoring thereafter. 
Lee et al (2013)(42) found similar crude rates  of  both  hyperkalemia and  AKI  when restricting 
their real-world systolic  heart failure study cohort to align  with the  RALES inclusion.  Similar 
inclusion criteria and monitoring were applied in the TOPCAT trial among patients with HFpEF; 
however, cumulative incidence of hyperkalemia was higher (~19% in the spironolactone group 
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vs. ~9% in placebo among randomized patients over the study period) than what was reported in 
RALES, and  drug  discontinuation  due to “abnormal renal function”  was  higher for 
spironolactone patients versus placebo patients (3.9% vs 2.3%, respectively; p=0.006).(113) Our 
study results  were consistent  with the  TOPCAT trial showing more  pronounced risks  with 
spironolactone use, and the findings from other studies, including those in various heart failure 
sub-populations like in  older  women and in those after an acute  myocardial infarction, except 
that AKI was more common in our cohort overal.(34, 43, 125) 
 
As expected, the absolute risk of both hyperkalemia and AKI with spironolactone use increased 
with lower eGFR; however, we observed no diference in relative risk for hyperkalemia or AKI 
associated  with spironolactone  by level  of  kidney function (interactions  not significant in as-
treated  or ITT).  Diferences in risk  by  kidney function could  not  be explored in  RALES and 
TOPCAT because those with higher SCr were excluded; however, other studies have observed 
relatively infrequent and  mild spironolactone-associated increases in  SCr, and  K, among those 
with reduced kidney function.(26, 30, 38-40, 118, 126) Similar to ACEi and ARB medications, 
studies have demonstrated an early reduction in eGFR with spironolactone in the seting of CKD 
and  diabetic  nephropathy,  but this appears to  be transient,  with litle evidence  of a  persistent 
reduction in the context of longer-term use.(29, 42, 43, 118, 127, 128) Also, among those with 
heart failure potentialy indicated for spironolactone, there are many other common risk factors 
which can al contribute to  hyperkalemia risk independent  of  one’s  kidney function like  older 
age, diabetes melitus, volume-depleting ilness, and use of ACEi, ARB, and other medications, 
making spironolactone’s safety chalenging to study in observational study setings.(31, 114-116, 
129)  Several clinical trials funded  by  both  government and industry sponsors are evaluating 
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spironolactone’s safety and eficacy in  patients  with  CKD, including those  with  ESRD, 
evaluating cardiovascular and renal endpoints. 
 
Despite the ongoing trials, more data are needed to beter understand whether spironolactone’s 
risks outweigh prospective benefits in patients who are curently exposed. Spironolactone is used 
among patients with various comorbidities, at diferent levels of SCr and K, and with exposure to 
various concomitant medications that can al make hyperkalemia or AKI more likely. In general, 
aldosterone antagonists are  not recommended in  heart failure  patients  with eGFR  <30 
mL/min/1.73m2 by the  American  Heart  Association (AHA),(99,  100) yet these  patients  have 
limited therapeutic options and may derive benefit from its pleiotropic pharmacologic properties; 
outside of its cardiovascular benefit,(26, 27, 38-40, 130, 131) some data suggest spironolactone 
may also slow the  progression  of  CKD.(28,  30,  31,  33,  103,  127,  128,  130,  132,  133) 
Nevertheless, we observed a marked increase in the incidence of these primary safety outcomes 
in patients with spironolactone use at lower eGFRs, but it is also clear that routine monitoring of 
SCr and  K is  waranted at al levels  of  kidney function.  With a  beter  understanding  of 
spironolactone’s safety profile in heart failure, ideal candidates for spironolactone can be chosen 
with the risks for hyperkalemia and AKI balanced accordingly. 
 
Our study has several notable strengths. We used a large, integrated EHR system with access to 
al  primary care  patient records across the  health system, including laboratory, inpatient, and 
outpatient data. Patients in the Geisinger primary care system generaly have litle atrition, with 
many  years  of  detailed records.  Mortality  data  were also available.  Our study also  had some 
limitations.  While many Geisinger  patients  have extended folow-up,  patients are relatively 
homogenous with respect to race and ethnicity.  We  used ICD-9/10  diagnosis codes for 
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comorbidities and outcomes; particularly for hyperkalemia and AKI, these codes are likely to be 
quite specific, and select for the  most severe cases.(134,  135)  Because  most  heart failure 
diagnosis codes are for unspecified heart failure, we could not diferentiate between reduced or 
preserved ejection fraction. 
 
4.6 Conclusions 
Spironolactone use was were relatively uncommon among patients on loop diuretics with heart 
failure. Concomitant use of spironolactone and a loop diuretic was associated with an increased 
risk  of  hyperkalemia and, to a lesser extent, AKI compared to loop  diuretic  use  without 
spironolactone,  with  no evidence  of risk  modification across the spectrum  of eGFR. 
Spironolactone  has  known  benefits and risks in  narower  patient  populations, and this study 
ofers insight into its safety  profile  under real-world conditions, specificaly among those  with 














Table 1C: Study population at T0, stratified by initiation of spironolactone 
 
 
Table 1C Key: T0 / baseline is the first loop diuretic order after initial heart failure diagnosis; Charlson Comorbidity 
Index (CCI); serum potassium (K); serum creatinine (SCr); estimated glomerular filtration rate (eGFR); heart failure 
(HF); cardiovascular disease (CVD); peripheral artery disease (PAD); acute kidney injury (AKI); angiotensin-
converting-enzyme inhibitor (ACEi); angiotensin I receptor blockers (ARB); potassium-sparing (k-sparing); for 
mean values, parentheses designate standard deviation (SD); CVD is a composite category including 
cerebrovascular disease/stroke, coronary artery disease, and myocardial infarction; time with HF is the mean time 
between initial HF diagnosis and first loop prescription after the initial HF diagnosis; proteinuria was defined using 
diagnosis codes; “ever initiators” include those who ever took spironolactone, even if it did not overlap with a loop 
diuretic. 
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Table 2C Key: estimated glomerular filtration rate (eGFR); “loop and spironolactone” represents concomitant use of a loop diuretic and spironolactone, “loop 
alone” represents use of a loop diuretic without spironolactone, “spironolactone alone” represents spironolactone use without a loop diuretic, and “none” is no 












Table 3C Key: Data shown are subdistributional hazard ratios (sHR) with loop as the reference; models were adjusted by age, sex, race, eGFR, K, time with HF, 
year of first loop order, CCI, history of hyperkalemia, AKI, CVD, PAD, diabetes melitus, cancer, cirhosis, ascites, atrial fibrilation, proteinuria, and prior use 
of anticoagulants, ACEi, ARB, other antihypertensives, antiarhythmics, cardiac glycosides, statins, thiazide diuretics, and potassium-sparing diuretics; time-
varying variables in fuly-adjusted models were eGFR, K, and combined ACEi or ARB use; “loop and spironolactone” represents concomitant use of a loop 
diuretic and spironolactone, “loop alone” represents use of a loop diuretic without spironolactone, “spironolactone alone” represents spironolactone use without a 
loop diuretic, and “none” is no use of either spironolactone or a loop diuretic.
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Table 4C: Hyperkalemia and acute kidney injury events for treatment and control groups by 
cohort “trial” year (Intention-to-treat analysis) 
 
Table 4C Key: Treatment group refers to patients using loop and spironolactone concomitantly; Control group 
refers to patients using loop without spironolactone; Control group patients can be included in subsequent cohort 
“trial” years as a treatment or control, but treatment group patients are not eligible for subsequent cohort “trial” 
years; patients were excluded if T0 K > 5.0 mEq/L. 
 
Supplementary Table S1C: Coding algorithms for outcomes and comorbidities 
 
 
Supplementary Table S1C Key: International Classification of Diseases (ICD); cerebrovascular disease (CEVD); 
coronary artery disease (CAD); myocardial infarction (MI) 
2004-2006 166 1,938 125 18 477 45
2007-2009 376 4,500 301 39 1,274 110
2010-2012 554 6,300 371 40 1,799 163
2013-2016 904 9,389 400 66 2,032 242
Pooled 2,000 22,127 1,197 163 5,582 560





Events in treatedTotal events Events in treated Total events 
Hyperkalemia Acute Kidney Injury
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Supplementary Table S2C: Study population used for intention-to-treat analysis, pooled and 




Supplementary Table S2C Key: Index date (T0); Charlson Comorbidity Index (CCI); serum potassium (K); serum 
creatinine (SCr); estimated glomerular filtration rate (eGFR); heart failure (HF); cardiovascular disease (CVD); 
peripheral artery disease (PAD); acute kidney injury (AKI); angiotensin-converting-enzyme inhibitor (ACEi); 
angiotensin I receptor blockers (ARB); potassium-sparing (k-sparing); for mean values, parentheses designate 
standard deviation; time with HF is the mean time between initial HF diagnosis and first loop prescription after the 
initial HF diagnosis; proteinuria was defined using diagnosis codes; CVD is a composite category including 




Figure 2C: Risk of hyperkalemia and acute kidney injury comparing treatment to control groups (Intention-to-treat analysis) 
 
* p<0.05 
Figure 2C Key: Inverse probability of treatment weights (IPTW); propensity score (PS); figure ploted on log scale; models were adjusted by age, sex, race, 
eGFR, K, time with heart failure relative to first loop prescription order, year of first loop order, time since first loop order, CCI, history of hyperkalemia, AKI, 
CVD, PAD, diabetes melitus, cancer, cirhosis, ascites, atrial fibrilation, proteinuria, and prior use of anticoagulants, ACEi, ARB, other antihypertensives, 




5.1 Synthesis of primary findings 
  
In a community-based cohort  of  older adults,  we  observed prevalent polypharmacy and 
potentialy inappropriate medication (PIM) use, with patients taking more medications and more 
PIMs at lower estimated  glomerular filtration rates (eGFR). Greater  numbers  of  medications 
were associated  with  greater risks for hospitalization and  death,  but  PIM  use  was  not. These 
findings suggest the benefits from routine  medication  management in  older adults including 
beter coordination of care between providers, and increased monitoring of kidney function. An 
improved accounting  of patients’ medications may  mitigate the risk  of adverse drug events in 
acutely susceptible  patients, specificaly reducing  unnecessary  or redundant  medications, but 
without improved pre-market data on medication safety in patients with chronic kidney disease 
(CKD), prescribing  guidelines wil continue to  be chalenged  by a lack of empiricaly-based 
eGFR thresholds for safe use. 
 
With respect to  guidelines  on  PIM  use  based  on  kidney function, there  were some  noted 
discrepancies  between  guidelines  on thresholds  where specific  medications  were  not 
recommended. The lack  of consistency observed between medication guidelines is likely a 
function of the limited information on safety in higher risk patients like older adults and those 
with CKD. This can create subjective prescribing guidelines that are reliant on consensus opinion 
or qualitative guidance, or use kidney function thresholds for safe use based on limited studies, 
and  using antiquated metrics or data. For example, potassium-sparing diuretics such as 
amiloride, triamterene, and spironolactone, and anticoagulants such as fondaparinux and 
dabigatran, appear to be particularly discrepant across the references used in our study. 
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Interestingly, we did not find an association between PIM use and morbidity and mortality in our 
study, which may have been due to our prevalent user design (i.e. creating a cohort afected by a 
“depletion  of susceptibles”), and/or  our  narow  definition  of  PIM  use that  did  not include 
medication dose.  Nevertheless, the  overal lack  of information  on  medication safety in those 
with  CKD, and  ostensible ambiguity across clinical guidelines, may  be contributing to 
deleterious consequences with serious efects on patient  outcomes. In  patients  with  CKD  who 
already  have  with limited therapeutic  options, the  benefits  of a  medication  may  outweigh the 
risks,  but  providers  may  get equivocal  or confusing information simply from consulting  with 
diferent  published  guidelines.(9,  13,  14,  77)  Therefore, beter understanding the safety  of 
medications across the spectrum  of  kidney function, and establishing empiricaly-based  kidney 
function thresholds  when risk is  outsized relative to any  potential  benefits should  be a  public 
health  priority given the  prevalence  of  kidney  disease worldwide. Incentivizing industry to 
conduct these studies in  new  drug applications submited for approval  moving forward  may 
require increased regulatory authority whereby marketing is contingent on establishing a safety 
profile in patient populations like those with CKD, where safety can not be infered and adverse 
drug events are common.  
 
We  used spironolactone as a case-study  of a  medication  with known risks,  but conflicting 
guidelines on its safety across kidney function. Because it was approved in a time when approval 
was  based  on limited  or  no renal  pharmacokinetic (PK) information,  particularly if  drug 
manufacturers were not seeking a specific label claim, there is uncertainty surounding its safety 
profile among those with CKD. Spironolactone has utility in refractory hypertension and severe 
heart failure, common comorbidities of patients with CKD, yet litle is known about what level 
of kidney function use is safe, and whether any cardiovascular benefits, or even potential renal 
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benefits, may ofset its  most serious risks  of  hyperkalemia and acute  kidney injury (AKI). 
Curently, the  American  Heart  Association (AHA)  guidelines (99,  100) recommend  no  use  of 
aldosterone antagonists in patients with heart failure (reduced or preserved ejection fraction) with 
eGFR  <30  mL/min/1.73m2,  but it is  unclear  how these  guidelines afect clinical  practice and 
which  patients are  ultimately  prescribed spironolactone given its established efectiveness. In 
order to assess its real-world safety across the spectrum  of  kidney function,  we first  needed to 
understand the incidence and  predictors  of  use in real-world clinical practice;  observed 
diferences in  who is  ultimately exposed  must  be taken into account  when assessing its real-
world safety. 
 
In two separate cohorts  of  patients  with  heart failure, less than  10%  of  patients initiated 
spironolactone within two years of their incident heart failure diagnosis, and patients with eGFR 
<30 mL/min/1.73m2 were the least likely to initiate spironolactone compared to other levels of 
kidney function; these patients also had the shortest duration of use. In addition, those with loop 
diuretic use and lower serum potassium were more likely to use the spironolactone. Our findings 
suggest that patients’ kidney function influences whether they are prescribed spironolactone, and 
may partly reflect providers’ knowledge of the curent  guidelines in  heart failure;  however, 
decisions  on  which  medications are  prescribed in patients are  often  more complex and 
multifaceted, and generaly based on a multitude of factors including, but not limited to, disease 
severity and comorbidities. Importantly, even though utilization  was lowest at lower eGFRs, 
these patients were stil prescribed the medication in the context of other comorbidities and with 
concomitant medications that  may  have increased their risk  of  hyperkalemia and  AKI.  With 
real-world safety  data  on spironolactone lacking, its  necessary that  providers have a  more 
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complete understanding  of these risks as to appropriately  balance them  with any  benefits, 
particularly among those where use is not necessarily recommended. 
 
Using integrated electronic  health record (EHR)  data from primary care patients with  heart 
failure in a Pennsylvania health system, we observed increases in the risk of hyperkalemia, and 
more modestly AKI, with the use of spironolactone and a loop diuretic compared to the use of a 
loop  diuretic  without spironolactone. While the absolute risks were highest among 
spironolactone users with lower eGFRs, as expected, the relative risks of hyperkalemia and AKI 
were not modified by renal function. This later point was a particularly interesting finding given 
an expected diferential risk in lower eGFRs  due to the compounding interactions  with 
concurent heart failure and with the use of a potassium-sparing diuretic drug; however, residual 
confounding by indication may have biased the interaction efect towards the nul.   Given the 
ongoing clinical trials investigating spironolactone’s eficacy with respect to cardiovascular and 
renal endpoints in advanced CKD and diabetic nephropathy, and the potential for expanded use 
to al heart patients (reduced or preserved ejection fraction), quantifying the real-world risks of 
hyperkalemia and AKI can beter equip providers curently treating patients, specificaly patients 
with limited therapeutic  options.  As an inexpensive  generic  medication  with  known  utility in 
heart failure, spironolactone’s risks  may  be tolerable in some patients  despite concurent 
comorbidities like CKD. 
 
5.2 Regulatory implications 
Our work exposed a fundamental flaw in the drug approval and regulatory process with respect 
to  data  on safety in  higher risk  patients like those  with  CKD.  When a  new  drug application 
(NDA) is submited for approval, the drug has gone through rigorous testing in pre-clinical and 
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clinical studies,  but the  medicine  often  has  not  been thoroughly tested in those  with 
compromised renal function, and that lack of information brings about ambiguity in how to use 
the  medicine in these patients. In  general,  patients  with reduced  kidney function are excluded 
from clinical trials during drug development because their kidney function impacts the PK of a 
drug puting them increased risk for adverse events. Without empirical evidence from pre-market 
testing, limited post-market studies, including observational studies, sometimes fil that void, and 
recommendations  become  based  on these limited  data.  This has consequences on patient 
outcomes in that some patients are channeled into potentialy less efective medications based on 
their kidney function unnecessarily,  while  others  may  be  prescribed a  medication that is 
potentialy less safe than an alternative.  
 
Regulations around studying drugs in those with CKD are inadequate in that presently there is no 
requirement that they be represented in pre-market clinical trials.(10, 11, 16, 18) Although there 
have been improvements in the proportion of NDAs summited with renal PK studies since the 
U.S.  Food and  Drug  Administration (FDA) first issued a “Guidance for Industry”  on the 
topic,(16)  many stil lack such  data,  particularly in  medicines approved  many  years ago, like 
spironolactone. The most efective method of colecting safety data in patients with CKD is to 
require their inclusion in studies during drug development; this method was utilized in 1993 to 
ensure women  were included in cardiovascular  drug trials.  One  way to more expeditiously 
instate this fundamental change in regulation is to alow Sponsors to conduct safety and eficacy 
trials for those  with  CKD separate from the  pivotal trials  used as the  basis for approval. To 
incentivize Sponsors even further, patent exclusivity could be granted for marketing in patients 
with CKD if safety and eficacy could ultimately be established in those studies. However, in the 
interim, FDA should continue to encourage Sponsors of  NDAs to conduct safety studies in 
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patients with reduced kidney function, and perhaps moving forward consider basing approval of 
a medicine on the NDA having adequate renal PK data, especialy in al drugs that are renaly-
cleared. Another way FDA could assert their authority and mandate these data are colected are 
through required studies after the  medicine is approved for  marketing; however, FDA’s 
regulatory authority is limited with respect to the designing, implementing, and enforcing post-
market study.(136) Also, this assumes that there is some basis for infering the drug’s safety in 
CKD based on other similar drugs or active pharmaceutical ingredients.  
 
One method that has become increasingly more common in drug development is population PK 
(popPK) analysis, specificaly when there are limited data on sub-groups that may be ultimately 
exposed to the drug.(137, 138) This method utilizes flexible mathematical models to predict PK 
(and  pharmacodynamic [PD]) parameters of a  drug using  data from  patients across several 
diferent clinical trial samples,  perhaps taking diferent  doses or on  diferent time schedules. 
These “opportunistic” samples are  derived from abstracting patient-level serum drug 
concentration data and other information, including demographics and comorbidities, from select 
patients in clinical trials, and  pooling  data for  greater statistical  power to estimate  dose-
concentration relationships, and for the ability to assess sources  of  variability in  drug 
concentration in  patient sub-groups  of interest. The  data  usualy come from clinical trials with 
unbalanced designs, from sub-studies that are not typicaly used in PK analyses, and from less 
rich data obtained in later phase trials.(139)  This is a cost-efective, post-hoc method to beter 
understand the PK (or PK/PD), and other safety data, in sub-populations of patients where only 
limited  data exist, and can  help to establish safe  dosing thresholds when studies  were  not 
powered adequately to define them. The FDA has issued two “Guidance’s” on popPK (1999 and 
2019),(139, 140) and encourages its use in the drug development process, where appropriate. 
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Nevertheless, despite a real need for beter safety and eficacy data for drugs used in the seting 
of  CKD, and available regulatory and/or analytical  methods to acquire such  data, the  problem 
persists.  In  2019,(17)  the American Society of Nephrology, the International Society  of 
Nephology, and the  European  Renal  Association issued a joint statement  pleading for  drug 
manufacturers to enrol patients  with  CKD in clinical trials  during  drug  development, and for 
regulators to intervene on this issue if  necessary.   Newer drugs for the treatment of type I 
diabetes that can potentialy benefit patients with  CKD  by mitigating further  decline in renal 
function like  Sodium-glucose  Cotransporter-2 (SGLT2) Inhibitors and  Dipeptidyl  peptidase  4 
(DPP-4) inhibitors  were  never tested in  patients  with eGFR <30  mL/min/1.73m2.  This is also 
true  of the  vast  majority coronary  heart  disease  drugs.(10)  Related to spironolactone,  while 
ongoing clinical trials assessing  both its cardioprotective and renoprotective  properties in 
patients with CKD wil presumably provide more quality data on its safety profile in the seting 
of reduced kidney function, the curent labeling should reflect the lack of data on its safety in this 
population,  particularly in regards to establishing an eGFR threshold for safe  use.  Until 
randomized controled trial data can fil that  ostensible  void, observational study  data, like the 
data  generated from  our studies, are critical for  quantifying risk across the spectrum  of  kidney 
function. 
 
5.3 Summary of public health significance 
• Polypharmacy is a common  yet modifiable risk factor for  morbidity and  mortality in 
older adults; measures should be taken to beter coordinate prescribing between providers 
to reduce unnecessary or inappropriate medications. 
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• PIM use based on kidney function is prevalent in older adults, and may be a function of 
medication labels and clinical guidelines lacking critical information on how and when to 
use  medicines in  patients with  CKD; regulatory agencies and  drug  manufacturers must 
make colecting pre-market renal PK/PD data a priority in drug development. 
• Spironolactone is an aldosterone antagonist with proven utility in heart failure, yet data 
on its safety across the spectrum of kidney function is limited as patients at the highest 
risk  of  hyperkalemia and  AKI,  namely those  with existing  CKD, were excluded from 
clinical trials. 
• Spironolactone initiation among  patients  with  heart failure is relatively rare  given the 
drug’s rather convincing cardioprotective efects and its  hypothesized benefit in 
mitigating CKD progression; those  with the lowest kidney function  were least likely to 
initiate the  drug, and  had the shortest  duration  of  use, compared to those  with  higher 
eGFRs. 
• Spironolactone initiation among loop diuretic users with heart failure was associated with 
an increase in the risk of hyperkalemia, and more modestly AKI, but these risks were not 
modified by eGFR; however, those with lower eGFRs had higher absolute risks of both 
common adverse efects. 
• Providers  must balance spironolactone’s risks with its known  benefits, and consider 
whether it is appropriate given a patient’s comorbidities; quantifying these risks in real-
world setings wil beter inform curent clinical practice guidelines on spironolactone use 
in heart failure treatment. 
• Curent labeling for spironolactone products should more explicitly acknowledge the lack 
of empirical evidence for an eGFR threshold that determines safe use, while at the same 
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time cautioning  patients and  providers  on its risks,  particularly among those  with  CKD 
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